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CONVENTIONS AND NOMENCLATURE
The basic 20-carbon skeleton of the prostaglandins has
been named prostanoic acid. The correct chemical name of
all prostaglandins, their metabolites and analogues can
be derived by reference to this structural formula.
These chemical names, although precise, are long and
tedious to use) therefore for the major prostaglandins,
trivial names are used.
Nine series of natural prostaglandins have so far been
described, designated by the letters A-I. The natural
prostaglandins have an S-hydroxyl group (or hydroperoxy
group in the case of PGG) at C-15 and contain a 13,14-
trans double bond. The degree of unsaturation of the
side chains is indicated by the subscript numeral (1, 2
or 3) after the letter. For all classes of prosta¬
glandins, these bonds appear at the same position and
possess the same stereochemistry. In addition to the 13,
14 double bond, members of the 2 series prostaglandins
contain a 5,6-cis double bond. Members of the 3 series
contain a third 17,18-cis double bond. The subscript a
refers to the configuration of the C-9 hydroxyl group.
The reader is referred to the following table. From
these examples, the trivial names of all common prosta¬
glandins can be deduced. In drawings of chemical
structures, stereochemistry is not implied unless
specifically indicated) a thickened or dotted line
denotes a substituent located respectively above or below
the plane of the paper.

































































The work described in this thesis is concerned with the
metabolism of arachidonic acid metabolites by blood plate¬
lets .
Incubation of arachidonic acid with washed blood platelets
(from human, horse, dog, cat and rabbit) revealed the
presence of novel arachidonic acid metabolites in addition
to those previously reported. Purification of the incu¬
bation extracts by liquid-gel partition chromatography
followed by a gas chromatographic-mass spectrometric exa¬
mination of a number of derivatives of selected chromato¬
graphic zones provided structural evidence for stereo¬
isomers of two trihydroxy acids (8,11,l2-trihvdroxy-5,9,14-
eicosatrienoic acid and 8 ,9 ,12-trihydroxy-5,10,14-eicosa-
trienoic acid) and isomers of an epoxy-hydroxy acid (10-
hydroxy-11,l2-epoxy-5,8,14-eicosatrienoic acid).
As the formation of these metabolites was not inhibited by
indomethacin but was inhibited by eicosa-5,8,11,14-tetra-
ynoic acid, it was postulated that the metabolites were
products of the platelet lipoxygenase pathway formed as a
result of transformation involving 12-hydroperoxy-5,8,10,-
14-eicosatetraenoic acid.
A range of pharmacological tests were applied to the newly
identified arachidonic acid metabolites. Pronounced
activity was only observed with 10-hydroxy-ll,12-epoxy-
5,8,14-eicosatrienoic acid in the chemotaxis assay.
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FIGURE 1.1 Proposed mechanism of lipid peroxidation
1.1 PATHWAYS OF ARACHIDONIC ACID AND
DIHOMO-,-LINOLENIC ACID METABOLISM
Introduction
The enzynic oxygenation reactions of all cis-5,8,11,14-
eicosatetraenoic acid (arachidonic acid) and to a lesser
extent all cis-8,11,14-eicosatrienoic acid (dihomo-y-
linolenic acid) represent an extensive area of bio¬
chemical and pharmacological research. The resultant
products are implicated in a wide range of physiological
processes.
For every lipoxygenase oxygenation type of reaction, the
minimum requirement is the presence in the molecule of
two cis double bonds separated by a methylene group. It
has been proposed that the mechanism involves abstraction
by oxygen of a methylene hydrogen atom to form a free
radical that is stabilised by re-arrangement to a conju¬
gated diene and that this stabilised radical combines
with a hydroperoxy radical to yield the hydroperoxy acid
(Figure 1.1) (Gurr and James, 1975). Assuming this
mechanism, arachidonic acid can be expected to undergo
peroxidation at six possible positions to yield products
with a hydroperoxy group at C-5, C-8, C-9, C-ll, C-12 and
C-15. Dihomo-y-linolenic acid can similarly be expected
to undergo peroxidation at four possible positions with
insertion of a hydroperoxy group at C-8, C-ll, C-12 and
C-15.
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The rest of this subsection outlines the principal infor¬
mation that has been determined concerning enzymic oxy¬
genation at each of these positions.
Oxygenation at the C-15 Position
Soyabean lipoxygenase is probably the most widely studied
plant lipoxygenase enzyme. Four isoenzymes have been
identified (Christopher and Axelrod, 1971j Christopher,
Pistorius and Axelrod, 1972; Christopher, 1972 and
Pistorius, 1974 - referenced within Bild, Ramadoss and
Axelrod, 1977). They share a common requirement for the
cis,cis-1,4-pentadiene system but differ in a number of
ways including pH optima, the nature of secondary re¬
actions they catalyse, the chemical nature of the sub¬
strate and positional specificity for the site of oxygen
insertion.
Of these isoenzymes, soyabean lipoxygenase-1 is perhaps
the most v/idely studied. Studies with this enzyme using
linoleic acid as substrate (Hamberg and Samuelsson,
1967j Christopher, Pistorius, Regnier and Axelrod, 1972)
have confirmed a positional specificity for attack at the
coS position with a weaker specificity for the tolO
position. Hamberg and Samuelsson reported that sub¬
strates which contained three of four double bonds such
as arachidonic acid or dihomo-y-linolenic acid only
formed products oxygenated in the w6 position. Treatment
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of arachidonic acid and dihomo-y-linolenic acid with
soyabean 1ipoxygenase-1 resulted in high yields (80-90%)
of 15L-hydroperoxy-5,8,11,13-eicosatetraenoic acid and
15L-hydroperoxy-8,11,13-eicosatrienoic acid respectively.
Small amounts of 15-hydroxy-5,8,11,13-eicosatetraenoic
acid and 15-hydroxy-8,11,13-eicosatrienoic acid have been
identified following incubation of arachidonic acid and
dihomo-y-linolenic acid respectively with preparations of
sheep vesicular gland (Hamberg and Samuelsson, 1967aj
Wlodawer and Samuelsson, 1973). Trace amounts of 15-
hydroxy-5,8,11,13-eicosatetraenoic acid were also
identified following incubation of arachidonic acid with
guinea pig lung homogenates (Hamberg and Samuelsson, 1974).
These hydroxy compounds were presumed to be formed from
the corresponding hydroperoxy compounds.
Recently, Borgeat and Samuelsson (1979) have reported the
formation of 15L-hydroxy-5,8,11,13-eicosatetraenoic acid
(15-HETE) following incubation of arachidonic acid with
human polymorphonuclear leukocytes (PMNL). Interestingly,
this product was detected only in human PMTIL and not
rabbit PMNL incubations. Although 15-HETE is synthesised
by human PMNL, it was reported not to have any significant
chemotactic activity for these cells (Turner and Lynn,
1978) .
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Oxygenation at the C-ll Position
The prostaglandins are a family of cyclopentane fatty
acids. They have been found to occur naturally in almost
every animal species and every cell or tissue which has
been studied. Many naturally occurring prostaglandins
and chemically synthesised analogues possess high bio¬
logical potency and show a great diversity of pharmaco¬
logical effects (for review, Horton, 1979).
The role of arachidonic acid and dihomo-y-linolenic acid
as prostaglandin precursors was discovered independently
by two groups of workers (Van Dorp, Beerthuis, Nugteren
and Vonkemann, 1964 J Bergstrflm, Danielsson, Klenberg and
Samuelsson, 1964).
A detailed examination of the mechanism of prostaglandin
formation has demonstrated that oxygenation occurs
initially at the C-ll position in the precursor acids.
Evidence for this mechanism was provided by a series of
experiments which are summarised in the following para¬
graph.
Klenberg and Samuelsson (1965) demonstrated, using
t
tritium labelled 8,11,14-eicosatrienoic acid, that the
hydrogen atoms in the C-8, C-ll and C-12 positions in the
precursor acid were retained in the same positions in PGEi
formed by sheep vesicular gland incubations. By using
5
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FIGURE 1.2 Mechanism of prostaglandin biosynthesis
18O2 gas in one biosynthesis of PGEi , it was then con¬
clusively demonstrated by mass spectrometric analysis
that the oxygen atoms at the C-ll and C-15 positions were
derived from molecular oxygen (Nugteren and Van Dorp,
1965j Ryhage and Samuelsson, 1965). Samuelsson (1965)
repeated these experiments using a mixture of 1602 and
1802 and established that the oxygen atom at C-9 in PGEi
was derived from one same molecule of oxygen as the
oxygen atom in the C-ll hydroxyl group. Further work
indicated that the hydrogen lost from C-13 during the
biosynthesis of PGEi had the L-configuration and that
neither 15L-hydroperoxy-8,11,13-eicosatrienoic acid nor
15L-hydroxy-8,11,13-eicosatrienoic acid were converted
to PGEi by the sheep vesicular gland preparations
(Hamberg and Samuelsson, 1967b).
All the evidence indicated that the first intermediary
in the biosynthesis of prostaglandins from dihomo-y-
linolenic acid was 11-peroxy-8,11,14-eicosatrienoic acid.
The initial attack at C-ll was considered to be followed
by cyclisation involving attack by oxygen at C-15, iso-
merisation of the 12,13 double bond into the 13,14
position and formation of an endoperoxide between C-9 and
C-ll (Figure 1.2).
In addition to PGEi, prostaglandins Fia and Di and 12L-
hydroxy-8,10-hepta.decadienoic acid (HHD) were also
identified as products of the sheep vesicular gland in-
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cubations (Hamberg and Samuelsson, 1966 j Nugteren, Beer-
thuis and Van Dorp, 1966 ) Granstrflm, Lands and Samuelsson,
1968) .
Using arachidonic acid as substrate, Hainberg and Samuels¬
son (1973) and Nugteren and Hazelhof (1973) independently
isolated an endoperoxide intermediate (named PGH2 ) which
contained a hydroxyl group at the C-15 position. An
additional endoperoxide with a hydroperoxy group at the
C-15 position was also isolated and named PGG2 (Nugteren
and Hazelhof, 1973j Hamberg, Svensson, Wakabayashi and
Samuelsson, 1974). In contrast to the previously dis¬
covered prostaglandins, the endoperoxides had a short
half-life of about five minutes in biological (aqueous)
systems.
Miyamoto et al (Miyamoto, Yamamoto and Hayaishi, 1974)
resolved two fractions of activity from a microsomal
fraction of bovine vesicular glands after solubilisation
with Tween 20 and DEAE-cellulose chromatography. One of
these fractions formed the unstable endoperoxide(s) when
incubated with dihomo-Y-linolenic acid and the second
converted the endoperoxide(s) into PGE^. These workers
demonstrated that indomethacin (10 pM) and aspirin (10 mM)
only inhibited the formation of the endoperoxide(s) from
dihomo-Y-linolenic acid and not the formation of PGE:
from the endoperoxide(s).
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By 1974, the prostaglandin endoperoxides were known to be
precursors to prostaglandins of the A, B, C, D, E and F
series and C1 7monohydroxy acids (HHD formed from PGG /
PGH
t and l2L-hydroxy- 5 , 8 ,10-heptadecattienoic acid (HHT)
formed from PGG2/PGH2). The biosynthetic pathway of PGA
and PGB compounds has not been elucidated. However,
these compounds can easily be formed from PGE compounds
by treatment with base (Anderson, 1969). An enzyme
which converts PGA i and PGA2 to PGB i and PGB2 has been
identified in plasma from several species. This con¬
version involves PGC compounds as intermediates (Jones,
1972).
In addition to the prostaglandins and HHT, PGG2/PGH2
were later shown to be precursors of an unstable compound
thromboxane A2 and its stable end product thromboxane B2.
This pathway was initially elucidated in human platelets
and is described in detail in the following subsection.
Thromboxane A2 is a potent inducer of platelet aggre¬
gation and a potent vasoconstrictor (Hamberg, Svensson
and Samuelsson, 1975J Needleman, Moncada, Bunting, Vane,
Hamberg and Samuelsson, 1976).
More recently, Vane and co-workers (Moncada, Gryglewski,
Bunting and Vane, 1976) have described an enzyme in blood
vessel walls that transforms the endoperoxides into PGI2
and its stable end product 6-keto-PGF1a. PGT^ is an un_
stable compound possessing essentially opposing effects





















aggregation and relaxant of smooth muscle (Moncada,
Gryglewski, Bunting and Vane, 1976a). The products of
this pathway and the implications of the opposing acti¬
vities of PGI2 and thromboxane A2 are discussed in more
detail in the following sub-section.
Oxygenation at the C-ll position results principally in
the formation of prostaglandins and thromboxanes. The
principal pathways involved in prostaglandin/thromboxane
biosynthesis are outlined in Figure 1.3 which refers
specifically to the products of arachidonic acid. Ana¬
logous series of prostaglandins/thromboxanes lacking the
5,6 double bond or having an additional 17,18 double bond
are formed if dihomo-y-linolenic acid or all cis-5,8,11,
14,17-eicosapentaenoic acid are used as substrates, the
exception being the lack of any natural prostaglandin
derived from dihomo-y-linolenic acid corresponding to PGI2 .
Relative to the prostaglandins, only very small amounts of
ll-hydroxy-5,8,12,14-eicosatetraenoic acid (11-HETE) and
11-hydroxy-8,12,14-eicosatrienoic acid were detected
following incubations of the respective precursor acids
with sheep vesicular gland preparations (Hamberg and
Samuelsson, 1967a^ Wlodawer and Samuelsson , 1973). In
contrast, if 11,14-eicosadienoic acid was used as sub¬
strate for the sheep vesicular gland preparations, then
ll-hydroxy-12,14-eicosadienoic acid was obtained in high
yields (Nugteren, Beerthuis and Van Dorp, 1967).
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Small amounts of 11-HETE were also detected in samples
from guinea pig lung homogenates incubated with arachi-
donic acid (Hamberg and Samuelsson, 1974). Recently,
Hubbard et al (Hubbard, Hough, Watson and Oates, 1978)
tentatively identified 11-HETE as a product following in¬
cubation of arachidonic acid with VX2 carcinoma tissue and
Roberts et al (Roberts, Lewis, Lawson, Sweetman and Oates)
tentatively identified 11-HETE as the major product of
arachidonic acid from mast cells stimulated with the iono-
phore A23187. It is interesting to note that Hubbard et
al reported that 11-HETE formation was not inhibited by
indomethacin. This would imply that indomethacin inhibits
the cyclisation reaction in the formation of the prosta¬
glandin endoperoxides from the precursor acids.
Oxygenation at the C-12 Position
A lipoxygenase enzyme was identified in blood platelets
which possessed w9 specificity (Hamberg and Samuelsson,
I974aj Nugteren, 1975). Arachidonic acid and dihomo-y-
linolenic acid were shown to be the best substrates with
12L-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) and
l2L-hydroxy-8,10,14-eicosatrienoic acid, the respective
products. The corresponding hydroperoxy compound (12-
HPETE) was identified as an intermediate in the conversion
of arachidonic acid to 12-HETE. These studies are des¬
cribed in more detail in Section 1.2.
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This type of lipoxygenase activity was reported to be
detected in a range of tissues (Nugteren, 1977). The
highest conversions were observed in those organs which
are known to accumulate platelets such as spleen and lung
(also Hamberg and Samuelsson, 1974). It was commented
that the smaller conversions observed in other organs
were probably also caused by platelets, since platelets
are present in blood throughout the microcirculation and
in principle, they can be expected to be present in
every organ.
The platelet lipoxygenase was not inhibited by indo-
methacin (300 jaM) or aspirin (500 pM) in contrast to the
platelet prostaglandin cyclo-oxygenase which was strongly
inhibited by indomethacin (30 pM) and aspirin (500 |iM) .
5,8,11,14-eicosatetraynoic acid (ETYA) (10 pM) strongly
inhibited both enzymes (Hamberg and Samuelsson, 1974a).
Hammarstrftm (1977) has reported that 5,8,11-eicosatriynoic
acid is a more selective inhibitor of the platelet lipoxy¬
genase in comparison to the prostaglandin cyclo-oxygenase
than ETYA.
12-HETE was reported to be chemotactic for human peri¬
pheral blood PMNL (Turner, Tainer and Lynn, 1975) and
these same workers have reported similar activity of the
12-hydroxy dihomo-y-linolenic acid product (Turner and
Lynn, 1978). They have proposed that these 12-hydroxy
compounds may possess roles as chemoattractants in
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inflammatory reactions. 12-HETE is reported to lack any
appreciable prostaglandin-like biological activity
(McGuire, Kelly, Gorman and Sun, 1978). It is inactive
on the gerbil colon, produces a weak biphasic response on
the blood pressure of the anaethetised rat and has no
significant effect on human platelet aggregation.
Oxygenation at the C-5 Position
The first reports of oxygenation at the C-5 position
were made by Borgeat and Samuelsson (1976) . Following
incubation of arachidonic acid with rabbit peritoneal PMNL
they identified 5D-hydroxy-6,8,11,14-eicosatetraenoic
acid (5-HETE) as the major metabolite. The corresponding
hydroperoxy compound (5-HPETE) was postulated as an
intermediate but was not isolated. 5-HETE formation was
not blocked by the prostaglandin cyclo-oxygenase inhi¬
bitor indomethacin (100 pM) or the platelet lipoxygenase
and prostaglandin cyclo-oxygenase inhibitor ETYA (65 |j.M) .
Later reports (Borgeat and Samuelsson, 1979 and 1979a)
indicated that small amounts of 5D,12D-dihydroxy-6,8,10,
14-eicosatetraenoic acid (5,12-DHETE) were also formed
by rabbit peritoneal PMNL incubates and that both 5-HETE
and 5,12-DHETE were formed by human peripheral blood PMNL
incubates. Using human peripheral blood PMNL, these
workers demonstrated that both products were stimulated
by the divalent cation ionophore A23187 whereas a third
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product, 15-HETE, was not stimulated. They then identi¬
fied an unstable 5,6-epoxide intermediate in the formation
of 5,12-DHETE from 5-HPETE (Borgeat and Samuelsson, 1979b
- referenced within Samuelsson, Borgeat, Hammarstrfim and
Murphy, 1979).
Slow reacting substance of anaphylaxis (SRS-A) is an
acidic lipid of unknown structure initially characterised
by Kellaway and Trethewie (1940). It is formed and re¬
leased from lung, leukocytes and other tissues during
allergic reactions as well as in response to a variety of
non-immunological stimuli, the most potent of which is the
ionophore A23187. SRS-A has potent contractile activity
for bronchial and ileal smooth muscle and is considered
to be a major cause of bronchospasm during asthmatic
attack in man. The stimulation of 5-HETE and 5,12-DHETE
by the ionophore A23187 raised the possibility that this
pathway was involved in SRS-A formation and release.
Using mouse mastocytoma calls, workers at the Karolinska
Institute (Murphy, HammarstrGm and Samuelsson, 1979 -
referenced within Samuelsson et al, 1979) have recently
identified the structure of a slow reacting substance and
proposed that it was formed from the previously described
unstable 5,6-epoxide intermediate in the formation of 5,
12—DHETE. SRS is reported to be a novel cysteinyl deri¬
vative of arachidonic acid with a hydroxyl group at C-5,














Figure 1.4 Leukotriene nomenclature
with the amino acid linked as a thioether to C-6. The
term leukotriene has been introduced for compounds which
like SRS are non-cyclised C20 carboxylic acids with one
or two oxygen substitutes and three conjugated double
bonds (Figure 1.4).
Recent investigations of the metabolism of arachidonic
acid by human peripheral blood lymphocytes (Parker,
Stenson, Huber and Kelly, 1979) have suggested that 5-HETE
was the major metabolite. Their major product co-
migrated with 5-HETE in a number of different TLC solvent
systems which adequately resolved 5-HETE, 12-HETE and
HHT from each other.
Clearly, this newly identified pathway and its biological
implications are an important area for further research.
Oxygenation at the C-8 Position
Incubation of dihomo-y-linolenic acid with rabbit peri¬
toneal PMNL under similar conditions to those used for
the converstion of arachidonic acid to 5-HETE was found
to produce 8D-hydroxy-9,11,14-eicosatrienoic acid (Borgeat
and Samuelsson, 1976). These workers suggested that it
was likely that the formation of 5-HETE and 8D-hydroxy-9,
11,14-eicosatrienoic acid were catalysed by two different
enzymes but did not rule out the possibility that they








Figure 1.5 Additional metabolites identified by Pace-Asciak
specificity for attack at the C-5 position. Under simi¬
lar incubation conditions, the formation of 5-HETE was
reported to be always favoured over 8D-hydroxy-9,11,14-
eicosatrienoic acid.
Pace-Asciak (1971) reported the formation of small amounts
of novel arachidonic acid metabolites in addition to
previously identified prostaglandins from sheep vesicular
gland incubations (Figure 1.5). The analogous compound 1
was also identified from dihomo-y-linolenic acid incu¬
bations. It is possible that formation of one or both of
these compounds may involve attack at the C-8 position.
No indication was provided as to whether or not these
compounds were products of the prostaglandin cyclo-
oxygenase pathway as the effect of indomethacin on their
formation was not determined.
Bild et al (Bild, Bhat, Ramadoss and Axelrod, 1978) have
isolated high yields (v40%) of a similar compound to Pace-
Asciak compound 1 and the analogous dihomo-y-linolenic acid
compound following incubation of an isoenzyme of soyabean
lipoxygenase (lipoxygenase-2) with arachidonic acid and
dihomo-y-linolenic acid respectively and subsequent
sodium dithionite treatment. This recently described
method of preparation of these metabolites is a feasible










Figure 1.6 Transformation of arachidonic acid by the double-
dioxygenation reaction of soyabean lipoxygenase-1
These same workers (Bild, Ramadoss, Lim and Axelrod, 1977)
have reported that under high enzyme concentrations of
soyabean lipoxygenase-1, arachidonic acid can be oxygena¬
ted at two sites on the same molecule to produce an 8,15-
di-hydroperoxide containing a conjugated triene according
to the reaction scheme in Figure 1.6.
This molecule is reported to inhibit platelet aggregation
induced by adenosine diphosphate (ADP), adrenaline and
collagen (Bild, Bhat and Axelrod, 1978).
Concluding Remarks
The enzymic oxygenation of both arachidonic acid and di-
homo-y-linolenic acid leads to a wide range of products
which possess diverse and at times opposing biological
effects. Recent evidence has prompted several researchers
to suggest that the more important biological actions of
these products are exerted by the unstable arachidonic
acid pathway intermediates, the endoperoxides, thromboxane
A2 and PGI2. The very recent investigations of Samuelsson
and co-workers concerning SRS have opened up another very
important area for further research.
The importance of these substances in physiology and
medicine and the challenge they pose to synthetic chemi¬
stry place them in the forefront of chemical, biochemical
and pharmacological investigations.
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1.2 THE ROLE OF ARACHIDONIC ACID METABOLITES
IN PLATELET FUNCTIONS
Introduction
The platelet is the anucleate derivative of the largest
cell in the bone marrow, the megakaryocyte. Platelet
functions include maintaining the integrity of the vascu¬
lature, promoting coagulation and responding to blood
vessel damage.
The formation of a mass of aggregated platelets at an
injury site on a blood vessel is one of the early events
in the development of a thrombus. Platelets change shape
and aggregate to many agents and it seems likely that
they have specific receptors on their surface for most of
the aggregating agents to which they are exposed in vivo.
These include thrombin, ADP, arachidonic acid metabolites,
antigen-antibody complexes, serotonin (5-HT), adrenaline,
vasopressin, platelet antibodies, viruses and bacteria.
During the aggregation response to many of these agents,
platelets undergo the release of their granule contents
and form prostaglandin endoperoxides and thromboxanes from
stored arachidonic acid. ADP can also be released which
augments the aggregation response to the primary stimulus
and the endoperoxides and thromboxanes themselves cause
aggregation and further release of ADP.
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There are at least three mechanisms which may be involved
in the aggregation response - ADP release, endoperoxide/
thromboxane formation and another independent mechanism
(or mechanisms). The other mechanism (or mechanisms) may
occur as a primary aggregation response either before or
concurrently with ADP release and endoperoxide/thromboxane
formation.
The rest of this sub-section traces the discoveries con¬
cerning the involvement of arachidonic acid metabolites
in platelet functions.
The Initial Indication of the Involvement of Arachidonic
Acid Metabolites in Platelet Functions
The possible involvement of arachidonic acid metabolites
in platelet physiology has been implicated since the late
1960's. Aspirin was reported to prolong bleeding time
(Mielke, Kaneshiro, Maher, Weiner and Rapaport, 1969) and
to have an inhibitory effect on the second wave of aggre¬
gation induced by collagen, adrenaline and ADP (Weiss and
Aledort, 1967*, Evans, Mustard and Packham, 1967; Morris,
1967; O'Brien, 1968). It was not however until 1971 that
it was discovered that aspirin and indomethacin inhibited
prostaglandin formation and raised the possibility that
the observed effects of aspirin on platelets may be linked
with prostaglandin formation (Smith and Willis, 1971; Vane
1971).
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The first indication of the formation and release of
prostaglandin cyclo-oxygenase products during aggregation
was the identification of PGE2 and PGF2 a following aggre¬
gation induced by various agents (Smith and Willis, 1970 *,
Smith, Ingerman, Kocsis and Silver, 1973). The bio-
synthetic capacity of PGE2 by platelets was also demon¬
strated by Clausen and Srivastava (1971) and Schoene and
Iacono (1974). It is worth noting, however, that the
latter two groups of workers used PGE co-factors in their
incubations.
The first evidence that products formed during or as a
result of arachidonic acid metabolism via the prostaglan¬
din cyclo-oxygenase pathway mediated shape change, aggre¬
gation and the release reaction was the observation that
arachidonic acid (in the order of 0.5 mM) induced these
factors when added to human platelet rich plasma (PRP) and
its effects were abolished by indomethacin or aspirin
(Silver, Smith, Ingerman and Kocsis, 1973j Vargaftig and
Zirinis, 1973', Smith, Ingerman, Kocsis and Silver, 1974).
A number of other fatty acids with similar chain length
and degree of unsaturation as arachidonic acid did not
cause aggregation of human PRP when tested in millimolar
concentrations (Silver et al, 1973).
Detailed Investigations of the Role of Arachidonic Acid
Metabolites in Platelet Functions








FIGURE 1.7 Major products identified following incubation of
arachidonic acid with washed platelet suspensions
gating stimulating substance, LASS) was reported to be
formed from arachidonic acid when it was incubated with
preparations of sheep vesicular glands. Extensive studies
indicated that the action of LASS was due to the prosta¬
glandin endoperoxides (Willis, 1974*, Willis, Vane, Kuhn,
Scott and Petrin, 1974).
A series of publications from the Karolinska Institute in
Sweden and Unilever Laboratories followed. These eluci¬
dated the principal pathways of arachidonic acid trans¬
formation in platelets and revolutionised the concepts
concerning the role of arachidonic acid metaboljtes in
platelet functions.
The first investigations by the Swedish workers involved
the elucidation of the transformation of arachidonic acid
by washed platelet suspensions (Hamberg and Samuelsson,
1974a). They identified three major products: 12L-hydroxy-
5,8,10,14-eicosatetraenoic acid (12-HETE), 12L-hydroxy-
5,8,1O-heptadecatrienoic acid (HHT) and 8-(l-hydroxy-3-
oxopropyl)-9,12L-dihydroxy-5,10-heptadecadienoic acid
(later designated thromboxane B2) (Figure 1.7). It was
demonstrated that only the latter two compounds arose from
pathways involving the prostaglandin cyclo-oxygenase path¬
way, as their formation was inhibited by indomethacin
(30 pM) , aspirin (500 pM) and ETYA (10 p.M) . The former
product was shown to be formed by a novel lipoxygenase
(Hamberg and Samuelsson, 1974a^ Nugteren, 1975) which
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involved the corresponding 12-hydroperoxy compound (12—
HPETE) as an intermediate. This intermediate was only
isolated in experiments using homogenised platelets and
semi-purified enzyme preparations. The lipoxygenase was
not inhibited by aspirin (500 p.M) or indomethacin (300 pM)
but was inhibited by the tetraynoic acid ETYA (10 |a.M) .
These results clearly indicated that transformation of
arachidonic acid to non-prostaglandin metabolites by
platelets occurred to a far greater extent than prosta¬
glandin formation.
These observations, in their turn, prompted a more de¬
tailed study on the effects of the endoperoxides on plate¬
let aggregation. They revealed the presence of a new
metabolite which was an unstable intermediate in the
formation of thromboxane B2 from the endoperoxides (Ham-
berg, Svensson and Samuelsson, 1975). The intermediate,
named thromboxane A2 (t, 32 sec, 37°C). was trapped by
addition of methanol, ethanol or sodium azide to sus¬
pensions of washed human platelets incubated for 30 sec
with arachidonic acid or PGG2. GC-MS examination of the
structures of the resulting derivatives demonstrated that
the intermediate possessed an oxane ring as in thrombox¬
ane B2 but lacked its hemiacetal hydroxyl group. Addi¬
tional experiments using 1®02 or [2H]8~arachidonic acid
in the formation of thromboxane B2 and CH302 H for the
trapping of thromboxane A2 , together with information of










Figure 1.8 Transformation of endoperoxides into thromboxanes
likely structure (Figure 1.8). Thromboxane A2 was shown
to be more potent than the endoperoxides in its ability
to induce irreversible aggregation in human platelets and
to contract the rabbit aortic strip (Hamberg, Svensson and
Samuelsson, 1975j Needleman et al, 1976).
Additional studies demonstrated that, in addition to
arachidonic acid, platelet aggregation induced by thrombin,
collagen, ADP and adrenaline was accompanied by release of
large amounts of thromboxane B2, HHT and 12-HETE. PGE2
and PGF2a accounted only for a very small part of the
transformation via the prostaglandin cyclo-oxygenase pathway
(Hamberg, Svensson and Samuelsson, 1974j Samuelsson, 1977).
At present, the relative roles of endoperoxides and throm¬
boxanes as aggregating agents is not clear. Needleman and
co-workers (Needleman, Minkes and Raz, 1976 J Needleman,
Raz, Ferrendelli and Minkes, 1977) have maintained that
the conversion of the endoperoxides to thromboxane A2 is
not a pre-requisi'te for induction of platelet aggregation.
Studies by Gorman and co-workers have led to somewhat
different conclusions (Gorman, Bundy, Peterson, Sun,
Miller and Fitzpatrick, 1977) as they deduced that ara¬
chidonic acid or PGH2 will not induce platelet aggregation
unless they are converted to thromboxane A2. Consider¬
ation of the literature leads to the conclusion that, in
all probability, the endoperoxides have an aggregating
action which can be dissociated from thromboxane A2.
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However, the latter compound is considerably more potent
and when thromboxane A2 or its stable end product, throm¬
boxane B2 , can be detected as a major product of an aggre¬
gation response, then thromboxane A2 can be considered as
the principal biologically active substance formed via
the prostaglandin cyclo-oxygenase pathway.
Oelz et al (Oelz, Oelz, Knapp, Sweetman and Oates, 1977)
reported that PGD2 was also synthesised by human platelets
(in comparable amounts to PGE2) in response to stimuli by
thrombin, collagen and adrenaline. Ali et al (Ali, Cerkus,
Zamecnik and McDonald, 1977) also reported that human
platelets stimulated with arachidonic acid or collagen
synthesised PGD2 in addition to thromboxane B2. They
found that the amounts of PGD2 were relatively small com¬
pared to thromboxane B2 (< 5%) in intact washed platelets
and platelets in plasma. PGD2 formation was reported to
increase in frozen/thawed platelet preparations. As PGD2
is known to be a potent inhibitor of platelet aggregation
(Nishizawa, Miller, Gorman and Bundy, 1975J Smith, Silver,
Ingerman and Kocsis, 1974), these workers have proposed
that the formation of PGD2 may represent a mechanism of
feedback inhibition.
There is no evidence that PGE2 , PGF2 a or PGD2 are formed
enzymatically by platelets and Nugteren (1977) has deduced
that they are chemical breakdown products of the unstable
endoperoxides because of the very small amounts of these
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prostaglandins relative to thromboxane B2 , 12-HETE and
HHT. These latter products have been shown to be formed
enzymatically.
Characterisation of Enzymes
The platelet lipoxygenase enzyme was found in the super¬
natant of the microsomal fraction of broken platelets.
Bovine platelets were used in the study (Nugteren, 1975).
This enzyme was shown to have an u>9 specificity and ara-
chidonic acid was the best substrate.
An enzyme was identified in the microsomal fraction of
horse and human platelets (Needleman et al, 1976) which
converted the endoperoxides (either PGG2 or PGH2) into
thromboxane A2. Detailed reports of the biochemical
properties of this enzyme (named thromboxane synthetase)
from bovine and human platelet microsomes followed (White
and Glassman, 1976^ Ho, Walters and Sullivan, 1976j Sun,
1977). More recently, Hammarstrttm and Falardeau (1977)
and Yoshimoto et al (Yoshimoto, Yamamoto, Okuma and
Hayaishi, 1977) have demonstrated the presence of prosta¬
glandin cyclo-oxygenase and thromboxane synthetase in
human platelet microsomes. The enzymes have been re¬
covered separately following solubilisation of the micro¬
somes with Triton X-100 and DEAE-cellulose chromatography.
These studies (also Hammarstrflm, Lindgren and Roos, 1979)


















Figure 1.9 Products identified following incubation of dihomo-y-linolenic
acid with washed platelet suspensions
thromboxane A2 and HHT formation and that IIHT is formed
directly from the endoperoxides and not from thromboxane
A2 . A wide range of inhibitors of this enzyme have been
discovered and investigated (Diczfalusy and Hammarstrflm,
1977j Hammarstrftm and Falardeau, 1977). Interestingly,
these include the platelet lipoxygenase product, 12-HPETE.
Only the hydroperoxy compound had inhibitory action where¬
as 12-HETE was reported to have no effect.
The Effects of Dihomo-y-linolenic Acid on Platelet Aggre¬
gation
Dihomo-y-linolenic acid, a polyunsaturated acid closely
related to arachidonic acid does not induce human platelet
aggregation and furthermore, can inhibit the aggregation
caused by various agents (Silver et al, 1973) Willis,
Comai, Kuhn and Paulsrud, 1974). In order to explain this
observation, the metabolism of this acid by washed plate¬
lets was investigated by Falardeau et al (Falardeau, Ham-
berg and Samuelsson, 1976). The major product was 12L-
hydroxy-8,10,14-eicosatrienoic acid and lesser amounts of
l2L-hydroxy-8,10-heptadecadienoic acid, PGE1, PGDi, throm¬
boxane B1j dihydroxv and trihydroxy acids were also detec¬
ted (Figure 1.9). The structures of two dihydroxy acids
were tentatively assigned as 8,15-dihydroxy-9,11,13-eicosa-
trienoic acid and 14,l5-dihydroxy-8,10,12-eicosatrienoic
acid - these compounds were resolved by TLC. Structures of
two trihydroxy acids which were not resolved, were tenta¬
tively assigned as 8,11,l2-trihydroxy-9,14-eicosadienoic
acid and 8,9,12-trihydroxy-lO,14-eicosadienoic acid.
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Comparable amounts of thromboxane Bi, PGEj and PGDi were
formed. The endoperoxides derived from dihomo-y-linolenic
acid (PGGi and PGHi) were reported to induce aggregation of
washed human platelets although they were less potent
than PGG2 and PGH2 . The lack of aggregatory effect of
dihomo-y-linolenic acid was not therefore explained by
the lack of aggregatory activity of the derived endo¬
peroxides but may at least be partly due to insufficient
formation of endoperoxides and thromboxanes by the plate¬
lets. Furthermore, significant amounts of PGEi were
formed from dihomo-y-linolenic acid and PGEj is well known
to be a potent anti-aggregatory agent (Kloeze, 1967j
Kinlough-Rathbone, Packham and Mustard, 1970).
Prostaglandin I2
Moncada et al (1976) described an enzyme in blood vessel
microsomes that transformed the prostaglandin endoperoxides
into an unstable substance (initially called PGX and later
designated prostacyclin or PGI2) that relaxed certain
blood vessels and inhibited platelet aggregation. PGI2
was reported to be 20-30 times more potent than PGEi and
5-10 times more potent than PGD2 as an inhibitor of plate¬
let aggregation (Gryglewski, Bunting, Moncada, Flower and
Vane, 1976). Prostaglandin I2 is formed by vascular
tissues from all species so far studied and is the main
metabolite of arachidonic acid in vascular tissue (for














(6-keto-PGFla lactol form) 6-keto-PGF!a keto form)
Figure 1.10 Transformation of endoperoxides into pgi2 and 6-keto-
PGF lot
A collaborative study between the Upjohn Company and Vane
and his co-workers at the Wellcome Research Laboratories
resulted in the elucidation of the structure of PGI2
(Johnson, Morton, Kinner, Gorman, McGuire, Sun, Whittaker,
Bunting, Salmon, Moncada and Vane, 1976). PGI2 was found
to be an unstable enol-ether,intermediate in the formation
of the stable 6-keto-PGFia (which is in equilibrium with
its lactol form) from the prostaglandin endoperoxides
(Figure 1.10).
Vane and co-workers have proposed a haemostatic hypothesis
whereby the endoperoxides serve as substrates for both
thromboxane A2 and PGI2 formation - substances with
opposing effects. Thromboxane A2 generated by platelets
promotes aggregation while PGI2 produced by vascular
endothelium inhibits aggregation. As corollaries, they
have proposed that:
i) the basal formation of PGI2 by vascular endothelium
may be important in the maintenance of the normal
integrity of vessel walls by inhibiting the ad¬
herence of platelets.
ii) PGI2 may normally limit thrombus formation.
iii) when a vessel wall is damaged, the formation of a




The principal pathways of arachidonic acid metabolism by
platelets have been elucidated. The role of the products
of the prostaglandin cyclo-oxygenase pathway in platelet
functions is considered to be more fully understood than
the role of the products of the lipoxygenase pathway.
Prostaglandin endoperoxides and thromboxanes are formed
and contribute to the aggregation response induced by a
number of agents: for example, arachidonic acid, collagen,
ADP, adrenaline and thrombin.
Thromboxanes are formed from the endoperoxides which are
also precursors for PGI2 which has opposing biological
properties to thromboxane A2 . Several important physio¬
logical processes including the haemostatic hypothesis
described previously may well be regulated by the
opposing biological actions of these two endoperoxide
products.
The function of the lipoxygenase pathway has not been
elucidated. However, it is interesting to note that two
Japanese workers (Okuma and Uchino, 1977) have reported a
correlation of platelet aggregability with platelet lip¬
oxygenase deficiency in patients with myeloproliferative
diseases and it has been suggested that 12-HETE formation
may be part of an elaborate control system for platelet
adhesion and aggregation.
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1.3 PROCEDURES FOR THE IDENTIFICATION OF
ARACHIDONIC ACID METABOLITES
The extremely small amounts of prostaglandins and other
arachidonic acid or dihomo-y-linolenic acid metabolites
normally present in biological samples necessitates the
use of highly sensitive and specific methods for their
analysis. Normally, solvent extraction and concentration
procedures, followed by purification are applied prior to
analysis to increase specificity and sensitivity. The
chromatographic mobility of a compound may itself pro¬
vide part of the evidence of its identity.
The choice of the most suitable chromatographic method
for sample purification depends principally on the com¬
pounds to be separated, their stability, the mass of the
sample and the nature of the sample matrix, and the number
of samples to be analysed. Methods used in this field
include paper chromatography, thin-layer chromatography,
gas and liquid chromatography (including silicic acid
chromatography, ion exchange chromatography, reversed-
phase partition chromatography, liquid-gel chromatography
and high performance liquid chromatography) (Ramwell,
Shaw, Clarke, Grostic, Kaiser and Pike, 1971J Horton,
1972", Brash and Jones, 1974J Pryde and Gilbert, 1979).
Biological assay methods have been used extensively for
the detection and estimation of prostaglandins and throm¬
boxanes. The advantages are good sensitivity (low nano-
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gram amounts) together with specificity for biologically
active compounds. Specificity can be enhanced by prior
chromatographic purification, by the use of pharmaco¬
logical antagonists of compounds other than prostaglandins/
thromboxanes and by assaying the sample on more than one
type of tissue preparation (parallel bioassay). The use
of bioassay enabled Samuelsson and his co-workers to de¬
tect the highly labile (t, 32 sec, 37°C) pro-aggregatory%
substance thromboxane A2 (Hamberg, Svensson and Samuels-
son, 1975) and Vane and his co-workers (Moncada, Gryglew-
ski, Bunting and Vane, 1976) to detect the labile
(activity lost with 10 min at 37°C at pH 7.5) anti¬
aggregatory substance PGI2 . The latter example involved
an elegant demonstration of using a series of different
tissues and detecting a material which produced a spectrum
of activity different from all known compounds. The bio¬
logical significance of these compounds would not have
been appreciated without the use of these biological
methods of analysis. The obvious disadvantage of bio¬
assay is that inactive metabolites will not be detected.
Radioimmunoassay (RIA) offers good specificity and is
capable of measuring metabolites in the nanogram and pico-
gram range. This method can be applied to any metabolite
provided that approximately 10 mg of the pure compound is
available for the initial raising of the antibody. The
unavailability of standards is a limitation to the use of
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RIA for the analysis of certain metabolites. A disadvan¬
tage is that the technique is time-consuming to set up
but this disadvantage can be compensated for by the speed
of analysis available with the established technique.
Cross-reactivity may cause problems when analysing struc¬
turally similar compounds (for example, prostaglandins
Flct and F2a). These difficulties are usually overcome
by prior chromatographic separation of the interfering
compounds. The specificity of an RIA method must be
thoroughly confirmed by cross-reactivity, accuracy and
precision tests as the technique will not provide evidence
of interference in any individual sample. In contrast,
when estimations are made by combined gas chromatography-
mass spectrometry (the reader is referred later in this
section), the analyst can observe a characteristically
shaped ion current response and scrutinse each individual
chromatogram for interfering substances. Ideally, the
accuracy of RIA results should be confirmed by another
analytical method, preferably gas chromatography-mass
spectrometry.
Infra-red and NMR spectroscopy have been employed for the
structural elucidation of arachidonic acid and dihomo-y-
linolenic acid metabolites (Bergstrftm, Ryhage, Samuelsson
and Sjovall, 1963) Anggard and Samuelsson, 1964) Granstrttm,
1971, 1972) Granstrflm and Samuelsson, 1971, 1971a, 1972)
Hamberg and Samuelsson, 1974a) Borgeat and Samuelsson,
1976, 1979). However, milligram quantities and very pure
samples are required for such analyses and therefore
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these techniques are completely unsuitable for the identi¬
fication of metabolites from small samples of tissue.
Ultraviolet spectroscopy is useful in certain cases, but
again, is too insensitive for most analyses and only pro¬
vides limited information. The method has been success¬
fully applied to the estimation of PGE, PGA and PGB levels
in human seminal plasma (ref Bygdeman and Samuelsson, 1964,
1965^ Horton, Jones and Marr, 1973).
Combined gas chromatography-mass spectrometry (GC--MS) has
been extensively used for the identification, structural
elucidation and quantification of arachidonic acid and
dihomo-y-linolenic acid metabolites. The nature of the
various polar functional groups in these metabolites
necessitates sample derivatisation prior to gas chromato¬
graphy in order to achieve thermal stability, volatility
and hence good gas chromatographic properties.
The carboxylic acid group is rendered less polar by con¬
version to an ester, most commonly the methyl ester. A
number of derivatives have been employed to protect
hydroxyl groups and these include the trimethylsilyl (TMS)
ether (Luukainer, Vanden-heuvel, Haahti and Horning,
1961) acetate (Bergstrflm et al, 1963) the boronate ester
(Brooks and Watson, 1967) and the tertiary-butyl di-
methylsilyl (t-BDMS) ether (Corey and Venkateswarlu, 1972).
A free ketone in the co-side chain of a prostaglandin or in
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the PGA or PGB cyclopentane ring need not be derivatised.
However, the 1,3 ketol moiety of the E series prosta¬
glandins is particularly labile and must be stabilised by
conversion of the ketone to an oxime (Vane and Horning,
1969*, Green, 1969) .
In conventional gas chromatography (GC), the column
eluant is usually monitored by flame ionisation detection
(FID) or electron capture detection (ECD). The limit of
detection using FID and ECD is in the order of 50 ng and
100 pg respectively. However, in most biological samples
there is a large excess of non-precursor acid derived
components which cause chromatographic interference and
it is this lack of specificity which precludes the use of
conventional GC in the analysis of metabolites. These
problems of insufficient specificity can be improved by
the simultaneous monitoring of mass and radioactivity, a
method which has proved useful in metabolism studies
(Hamberg and Samuelsson, 1971", GranstrBra, 1972), but only
satisfactorily overcome by employing a mass spectrometer
as a GC detector (GC-MS).
In a mass spectrometer, a volatilised compound is sub¬
jected to ionisation and fragmentation. The individual
positively charged ion fragments are resolved in the
analyser unit and recorded as a mass to charge ratio (m+/e
value, predominantly charge, e = 1). A mass spectrum may
be likened to a fingerprint as it is characteristic of the
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original molecule. This spectrum combined with the
chromatographic retention time of the derivative provides
a highly specific method of identification. The gas
chromatograph is interfaced to the mass spectrometer by
means of a separator, the purpose of which is to remove
the GC carrier gas from the analytical sample as it enters
the mass spectrometer. These two instruments are highly
compatible in terms of quantities of material analysed,
response time and requirement for sample volatility.
Compounds can be identified by comparison of their
chromatographic retention time and mass spectra with those
of reference compounds. The structure of new metabolites
can be determined from an examination of the chromatogra¬
phic properties and mass spectra of a variety of deriva¬
tives. The following references are excellent examples of
this application (ref. GranstrSm and Samuelsson, 1971,
1971a; Granstrfim, 1972 ; Hamberg and Samuelsson, 1974a*,
Johnson et al, 1976; Fenwick, Jones, Naylor, Poyser and
Wilson, 1977; Borgeat and Samuelsson, 1976, 1979a).
Chemical modification or degradation of an identified
material followed by GC-MS examination of the products can
provide additional useful structural information.
The principal information obtained from a comparison of
the most frequently used derivatives can be summarised as
follows. In order to determine which of the ion fragments
in the methyl ester spectrum of an unidentified metabolite
contain the ester group, the spectra of methyl and ethyl
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esters are compared. All the ion fragments which are
fourteen mass units higher in the ethyl ester spectrum
will contain the ester moiety. The number of double
bonds may be determined by hydrogenation of the material.
On most occasions , the resultant spectrum will be simpler
to interpret than the original spectrum and hence provide
additional information. The presence (or absence) of a
ketone group can be determined depending on whether or
not the molecule will form an oxime and similarly, the
presence of a 1,2 or a 1,3 diol confirmed by the formation
of a boronate derivative. By comparison of spectra of
different oximes (or boronates), it can be determined
whether or not a particular ion fragment contains the
oxime (or boronate) moiety which aids the interpretation
of these spectra. These GC-MS procedures in conjunction
with other analytical techniques can enable the structure
of low microgram quantities of a compound to be deter¬
mined.
In addition to the use of GC-MS to obtain a fingerprint
mass spectrum, it can be used in the selected ion moni¬
toring (also called multiple ion detection) mode. The
mass spectrometer is set to monitor only ion fragments of
interest. Usually, these are high relative abundance ion
fragments in the mass spectrum of the compound to be
detected. Throughout a GC run, the ions are focussed
alternately on the detector and their intensities are
recorded separately as single ion chromatograms. This
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method of detection offers much higher sensitivity than
recording the whole spectrum of ions and an additional
advantage is that individual components may be monitored
over the complete time of elution of a GC peak as distinct
from a few milliseconds per ion when a mass spectrum is
recorded.
In the selected ion monitoring mode, the mass spectro¬
meter can be used both qualitatively and quantitatively.
Qualitatively, it is useful to identify smaller amounts
of material than would be detected by recording a
complete mass spectrum and also to determine whether or
not different ion fragments possess the same single ion
chromatographic profile. Such information can indicate
whether or not the different ion fragments being moni¬
tored are derived from the same compound. It may also be
useful to determine whether a single ion chromatographic
profile is identical to the total ion chromatographic
profile. This approach has been applied in Sections 3
and 4 of this thesis.
Quantitative GC-MS employs monitoring the response of the
sample relative to an internal reference standard and
comparing the response to a set of analytical calibration
standards containing the same fixed amount of internal
reference standard. The reference internal standard
chosen is usually an analogue of the compound to be
analysed and ideally is a stable isotope of the compound.
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These stable isotopes are normally formed by replacing
selected hydrogen atoms by deuterium in various positions
of the molecule (for prostaglandins, di* compounds
containing two deuteriums on C-3 and C-4 are normally
used). A fixed amount of internal reference standard is
added to each sample at the earliest possible stage in the
analytical sequence, usually before the first extraction
step and can therefore compensate for varying efficiencies
during extraction, purification and derivatisation. A
stable isotope internal reference standard and unlabelled
standard compound will have virtually identical chromato¬
graphic characteristics and will not be distinguished
until final detection by the mass spectrometer. At this
stage, the instrument is set to record the selected ion
chromatograms at the corresponding m+/e value of the
labelled and unlabelled compounds. A calibration curve
may then be prepared by plotting the peak response ratio
of the standard/internal reference standard against the
amount of standard in the calibration standards and a
comparison of the peak height ratio of samples enables
their quantification. This provides the most specific
assay method for the quantitative estimation of small
amounts of lipids present in complex biological mixtures.
The sensitivity of the method depends on the cleanliness
and nature of the derivatised sample - generally low
nanograms and on occasions picograms of material can be
assayed.
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The application of combined gas chromatographv-mass
spectrometry in order to provide qualitative and quanti¬
tative information on metabolites make it an invaluable
tool. It is unique in its ability to provide structural
information on very small amounts of material - essential
information in this area of work. However, the sole use
of GC-MS is insufficient. It should ideally be used in
conjunction with biological assay methods as only bio-
assay can detect short-lived intermediates and provide a















Prostaglandins A2 , B2 , D2 , E2 , F2Ct, 11,9-epoxymethano-
H2 and thromboxane B2 were obtained from Dr. J. E. Pike of
the Upjohn Company, Kalamazoo, Michigan, U.S.A.
10a, lla-epoxy-1 l-deoxy-PGF2 a and 10f3, 11B-epoxy-ll-deoxy-
PGF2 a were prepared by Dr. R. L. Jones by treatment of
PGA2 according to the reaction scheme shown in Figure 2.1.
The products of the hydrogen peroxide/sodium hydroxide
reaction were subjected to liquid-gel chromatography
which resulted in the separation of two isomeric epoxides.
These two epoxides were assigned the a and 3 configurations
following GC-MS examination of their products after treat¬
ment with aluminium mercury amalgam. One compound yielded
a product identical with PGE2 and this epoxide was assigned
the a configuration and hence the other was assigned the 6
configuration. Further treatment of these two isomeric
epoxides with sodium borohydride resulted in the two re¬
quired products whose structure was confirmed by GC-MS.
Each product chromatographed as a single zone on LGC, a
single spot on TLC and a single peak on GC and it was
considered that these products contained an a hydroxyl
group.
The methyl ester of oleic acid epoxide was prepared by











Figure 2.2 Preparation of lipophilic gel
ester of oleic acid in dichloromethane with a slight
excess of m-chloroperbenzoic acid for 1 h at 0°C.
Arachidonic acid (99%, Grade 1) was purchased from Sigma
Chemical Co., St. Louis, Missouri, U.S.A. The purity was
checked.by TLC after each delivery and on one occasion
when TLC indicated that there was greater than 10% im¬
purity present, the material was purified by liquid-gel
chromatography before use. The arachidonic acid was then
prepared and sealed in ampoules under nitrogen as a 10 mg.
ml ^ solution in re-distilled ethanol. This storage pro¬
cedure was shown by TLC to be satisfactory.
1-1 ''C-Arachidonic acid (60.2 mCi.mmol , 197 p.Ci.mg was
purchased from the Radiochemical Centre, Amersham, England
and was prepared and stored as a 10 |j.Ci.ml ^ solution in
re-distilled ethanol.
Lipophilic Gels
Sephadex LH-20 was purchased from Pharmacia Fine Chemicals,
Uppsala, Sweden. Treatment of this gel with l,2-epoxy-3-
phenoxy propane (K & K Laboratories Inc., Hollywood,
California, U.S.A.) in dry dichloromethane, with boron
trifluoride etherate as catalyst resulted in a product
which contained 33% by weight of the phenoxyhydroxypropy1
residue (Figure 2.2). This gel had been prepared pre¬





Grams per 5 litres
Krebs Tyrode Earles Salts Krebs -Hensel eit*
NaCl 34.5 40.00 34.00 9.00
KC1 1.75 1.00 2.00 0.46
CaCl2 1. 40 1.00 1.00
MgSOi. . 7II2 0 1.45 1.30 0. 50 0.38
NaHjPO„.Hj 0 0 .25 0.62
Glucose 10.00 5.00 5.00
NallCO, 10. 50 5.00 11 .00
Naj HPOit . 2H2 0 2.98
KHjPO^ 1.60 0.21
Phenol Red 0.25
*pH adjusted to 7.4 with IN IIC1
Reagents
Analytical grade solvents and inorganic chemicals were
used throughout. Toluene, hexane, dichloroethane and is
propanol were HPLC solvents from Rathburn Chemical Co.,
Walkerburn, Scotland. Pyridine was re-distilled and dri
over potassium hydroxide pellets. The suppliers of
chromatographic materials and reagents used for derivati
sation are given in the appropriate text. The standard
salt solutions used in the course of the study are
described in Table 2.1.
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TABLE 2.2
Composition of washing medium
A. 0.9% (w/v) sodium chloride in distilled water (0.11 M)
B. Tris(hydroxymethv1)amire/HCl buffer (0.15 M)
9.33 g salt/500 ml distilled water
cone HC1 added dropwise to pH 7.4
C. Di-sodium ethylene diaminetetra-acetic acid/NaOH
buffer (0.08 M)
14.33 g salt/500 ml distilled water
cone NaOH added dropwise to pll 7.4
A : B : C
Washing medium
90:8:2
2.2 TREATMENT OF BLOOD
Preparation of Platelet Rich Plasma
Blood obtained from healthy human volunteers, v/ho had not
taken aspirin for 10 days, was collected from the ante-
cubical vein in 0.2 volume of acid citrate dextrose solu¬
tion (3 g glucose and 2 g disodium hydrogen citrate/120 ml
distilled water) in polypropylene centrifuge tubes.
Platelet rich plasma (PRP) was obtained after centrifu-
gation at 200 xg for 15 min at room temperature. The
upper plasma layer was aspirated into clean centrifuge
bottles.
Blood from dog, cat and rabbit was obtained from animals
housed in the Pharmacology Department and was similarly
treated (the cat had been treated with indomethacin,
Section 2.9.5). The horse blood was obtained from the
local slaughter house and was the simplest to handle as
the red cells sedimented after standing at room tempera¬
ture for approximately 30 min following arrival, allowing
the PRP to be easily aspirated off.
Preparation of Washed Platelets
Washed platelets were prepared essentially as described by
Hamberg et al (Hamberg, Svensson, Wakabayashi arid Samuel-
sson, 1974). This involved the addition of three volumes
of washing medium (Table 2.2) to the PRP and centrifu-
43
gation at the minimum g force (approximately 600 x g) re¬
quired to "spin down" the platelets. The supernatant
buffer was then removed and the remaining platelet pellet
re-suspended in Krebs-Henseleit medium (pH 7.4) which
contained neither calcium ions nor glucose. If platelets
remained in the supernatant, this procedure was repeated.
It was determined that the platelets re-suspended more
readily and satisfactorily if they were spun down at
their minimum g force in centrifuge bottles with a large
bottom surface area as this prevented clumping and aggre¬
gation of the platelets.
Three day old platelet concentrate obtained from the Blood
Transfusion Service, Edinburgh Royal Infirmary was used
on several occasions and was treated in a similar manner.
The concentrate was diluted with the washing medium and
the small number of red cells present removed by centri-
fugation at 200 x g for 15 min. The upper layer of plate¬
let rich buffer was aspirated into clean bottles and the
platelet pellet was obtained by centrifugation and re-
suspended as described above.
When the effects of indomethacin on the products of the
platelet incubation were investigated, the PRP was divided
into two equal volumes and indomethacin (2 mM solution in
ethanol) was added to one volume to give a final concen¬
tration of 10 p.M and an equal volume of ethanol was added
to the other sample for control purposes. The washed
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platelets were then prepared as described previously and
the indomethacin again added to the treated sample when
the platelets were re-suspended in Krebs-Henseleit buffer.
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2.3 INCUBATION AND EXTRACTION CONDITIONS
Incubation Conditions
The washed platelet suspensions (at an approximate con-
8 9-1
centration of 5 x 10 to 5 x 10 ml ) were heated to
37°C in a water bath and arachidonic acid was added in a
small volume of ethanol and incubated at 37°C. Unless
otherwise stated, the final arachidonic acid concen¬
tration was 165 )j.M and incubations were carried out for
30 minutes. The final concentration of ethanol was nor¬
mally 1% (v/v) and never greater than 5% (v/v) . 1- 1 ^C-
Arachidonic acid (specific activity 120 pCi.mmol "*") was
added as tracer with the unlabelled arachidonic acid to
incubates where the products were to be subjected to
liquid-gel chromatography.
When incubations were carried out to determine the effects
of indomethacin or ETYA on the products of the incubation,
the platelets were pre-incubated for 5 min at 37°C with
these inhibitors before the addition of the arachidonic
acid. Control samples were prepared and pre-incubated in
a similar manner.
In experiments to determine the relative amounts of
thromboxane B2 and THETA produced by washed platelet and
PRP incubates, the PRP was divided in two equal volumes
and washed platelets were prepared from one volume as
described previously. Two volumes of Krebs-Henseleit were
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added to the PRP and the washed platelet pellet was re-
suspended in the corresponding volume of buffer. Incu¬
bations with arachidonic acid (165 )j.M in the washed
platelet suspension and at three times this concentration
in the PRP sample in attempts to compensate for protein
binding (Nugteren, 1977j Smith, Ingerman and Silver, 1977))
were carried out at 37°C for 30 min.
After the required time, incubations could be stopped by
the addition of five volumes of ethanol to the platelet
suspensions. This procedure was adopted in experiments
to compare the relative amounts of products after different
incubation times, to compare the products from washed
platelets and PRP incubates and when the products of
washed platelet incubates involving small volumes of
buffer were investigated. However, when large volumes
were being handled, this procedure was clearly impractical
and the addition of ethanol was omitted from the procedure.
The incubation mixtures were then centrifuged at 600 x g
for 20 min to remove the platelet material and the super¬
natant retained for extraction. In the case of incubates
quenched by the addition of ethanol, the ethanol/water
mixture was removed under reduced pressure on a rotary
evaporator at 35°C and the residue re-constituted in
distilled water prior to extraction.
Extraction Conditions
Following acidifcation to pH 3.5 - 4.0 with IN hydro-
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chloric acid, the products of the platelet incubation
were extracted three times with two volumes of diethyl
ether. The combined organic phase was washed once with
distilled water (l/10th volume) to remove traces of salts
and acids, then taken to dryness under reduced pressure on
a rotary evaporator at 30°C.
Non-polar lipids (for example the unreacted arachidonic
acid) were routinely removed by partition of the organic
extract between 33% aqueous ethanol and petroleum ether
(BP 60-80°C) (equal volumes; partitioned twice). Evapo¬
ration of the alcoholic phase yielded a residue con¬
taining the polar lipids which was sufficiently clean for
examination by GC-MS without further purification. This
further partition was omitted in samples prepared for the
isolation of EPHETA (Sections 4 and 5) as the maximum
amount of this compound was required and as this product
was not very polar, it was considered possible that a
significant amount of the material might partition into
the petroleum ether. These samples for the preparation of
EPHETA were subjected to liquid-gel chromatography.
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2.4 PREPARATION OF DERIVATIVES
Methyl (Me) and ethyl (Et) esters were prepared by treat¬
ment of a methanolic Solution of the acid with excess
diazomethane and diazoethane respectively. The methanol
was required to catalyse the reaction (Schlenk and
Gellerman, 1960). After five minutes at room temperature
the sample was blown to dryness and vacuum desiccated.
Diazomethane was prepared by reaction of ethereal N-
methy1-N-nitroso-p-toluene-sulphonamide (Aldrich Chemical
Co., Gillingham, England) with aqueous potassium hydroxide
and ethanol and transferred into fresh diethyl ether with
the aid of a stream of nitrogen. Diazoethane was pre¬
pared by reaction of ethereal N-nitrosoethyl urethane
(Fluka AG, Buch, Switzerland) with ethanolic potassium
hydroxide and transferred into fresh diethyl ether with
the aid of a stream of nitrogen and gently warming the
reaction mixture in a water bath. Both ethereal solutions
could be satisfactorily stored at -20°C for short periods.
Trimethylsilyl ethers (TMS) were prepared by dissolving
the esterified material in 30 p.1 bis(trimethylsilyl)tri-
fluoroacetamide (BSTFA) containing 1% trimethylchloro-
silane (Sigma Chemical Co., St. Louis, Missouri, U.S.A.).
Reaction was carried out for 20 min at 60°C or on several
occasions left to proceed overnight at room temperature
and the sample then heated on the following morning prior
to GC-MS analysis.
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Methyl oximes (MO) and butyl oximes (BuO) were normally
prepared by treatment of the esterified material with
50 )j.l of 5 mg.ml solutions of methoxyamine hydrochloride
(Supelco Inc., Bellefcnte, Pennsylvania, U.S.A.) and
butoxyamine hydrochloride (prepared by Dr. N. H. Wilson
in this laboratory) in pyridine respectively. The re¬
action was left to proceed overnight at room temperature,
the sample was heated at 60°C for 40 min on the following
morning and then blown to dryness. An alternative method
of oximation (Jones, 1972) involved treating the esteri¬
fied material with a 5 mg.ml solution of the appropriate
amine hydrochloride in 1M sodium acetate buffer (pH 4)
containing 20% ethanol in a similar manner. The material
was extracted with two volumes of diethyl ether and the
extract blown to dryness. Samples were vacuum desiccated
and treated with BSTFA prior to GC-MS analysis.
Butyl boronate (n-BuB) derivatives were prepared by treating
the esterified material with 50 p.1 of a 5 mg.ml solution
of n-butane boronic acid (Venton Alfa Products, Beverley,
Massachussettes, U.S.A.) in 2,2-dimethoxypropane (Aldrich
Chemical Co.) at 60°C for 2 h. The sample was then blown
to dryness, vacuum desiccated and treated with BSTFA prior
to GC-MS analysis.
Catalytic hydrogenation of the compounds was achieved by
bubbling hydrogen through a methanolic solution of the
esterified material containing platinum oxide as catalyst,
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at room temperature for 2 h. The solution was then fil¬
tered through a Whatman No. 50 filter paper (W&R Balston
Ltd., Maidstone, England) and the sample blown to dryness
and vacuum desiccated prior to further derivatisation and
GC-MS analysis.
Reduction of an epoxide with lithium aluminium hydride
(LiAlH^) (Koch-Light Laboratories Ltd., Colnbrook, England)
involved dissolving the esterified material in dry tetra-
hydrofuran in an ampoule. The LiAlH^ was then added and
the ampoule carefully sealed under nitrogen and heated at
60°C for 72 h. After this time, the ampoule was care¬
fully opened and the contents transferred into a small
volume of distilled water. The solution was adjusted to
pH 4 with IN hydrochloric acid and then extracted three
times with two volumes of diethyl ether. The sample was
blown to dryness and vacuum desiccated prior to further
derivatisation and GC-MS analysis.
The conditions employed for the ring opening of an
epoxide with trimethylchlorosilane and pyridine to form a
chlorohydrin-TMS adduct were essentially as described by
Harvey et al (Harvey, Johnson and Horning, 1972) and
involved heating the esterified material in a mixture of
trimethylchlorosilane (Sigma Chemical Co.) (10 |il) and
pyridine (20 p.1) at 60°C for 30 min. BSTFA (20 (il) was
then added in order to silylate any underivatised
hydroxy1 groups prior to GC-MS analysis.
Figure 2.3 Diagram of equipment used for liquid-gel
chromatography
2.5 LIQUID CHROMATOGRAPHIC METHODS
Liquid-Gel Chromatography (LGC)
A glass column (45 cm length, 3 cm diameter) was fitted
with a constant pressure solvent reservoir. The column
was packed with an equilibrated slurry of gel and solvent
held in place by a glass wool plug and silanised sand
(Figure 2.3) and eluted for at least 12 h before commence¬
ment of the first chromatographic separation.
Twice in the course of the study, a decrease in chromato¬
graphic resolution made it necessary to clean the gel.
This involved unpacking the column and treating the gel
with chloroform/methanol/glacial acetic acid (50/50/1).
The gel was mixed with this cleaning solvent and the
solvent decanted to waste. This procedure was repeated
several times. The gel was then re-equilibrated in the
required mobile phase and packed as described previously.
Samples were applied to the column dissolved in approxi¬
mately 2 ml of the mobile phase. An advantage of the
toluene based systems used was their good solvent solu¬
bility properties to the samples in comparison with
hexane/chloroform mixtures which are often used for liquid
gel chromatography. The height of the column outflow was
adjusted to give a constant flow rate of approximately
25 ml.h ^. Samples were collected on a fixed time basis
by the use of a fraction collector (Instrument Specialities
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Co., Nebraska, U.S.A.) and those fractions containing the
arachidonic acid derived products from the platelet incu¬
bates were determined by liquid scintillation counting.
A chromatogram was obtained by plotting CPM against
fraction number which indicated distinct radioactive
zones (Figure 3.6). Fractions from these zones were
bulked. When zones were not completely resolved, only
the middle fractions from each zone were retained. The
eluting solvent was removed from the bulked fractions
under reduced pressure on a rotary evaporatory at 35°C,
the samples vacuum desiccated and stored in methanol at
-20°C prior to analysis. They were analysed as soon as
possible after preparation.
Two solvent systems were routinely used:
toluene/1,2-dichloroethane/ethariol (50/50/1) (LGC 1)
toluene/1,2-dichloroethane/ethanol (100/100/5)
+ 0.1% acetic acid (LGC 2).
Thin-Layer Chromatography (TLC)
TLC was carried out using silica gel plates (5 cm x 20 cm,
0.25 mm silica) (Merck AG, Darmstadt, Germany) and silica
gel plates with a pre-adsorbent area for facilitated
loading (Whatman Inc., Clifton, New Jersey, U.S.A.).
Constant solvent saturation within the tank was achieved
by lining the walls with filter paper. Solvent was added
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to cover the bottom of the tank, to a depth of approxi¬
mately 6 mm, and eluted up the filter paper before use.
Arachidonic acid solutions were routinely checked for
specified purity by spotting 100 pg of a methanolic solu¬
tion onto a plate which was eluted with diethyl ether
containing 1% glacial acetic acid. The plate was visua¬
lised by spraying with 10% phosphomolybdic acid in
ethanol followed by heating at 100°C for 5-10 min. On
other occasions, methanolic solutions of material from
platelet incubates were applied to the plate and
following development, the radioactive zones were detected
using a Panax radiochromatogram scanner.
High Pressure Liquid Chromatography (KPLC)
HPLC was performed using a Partisil PXS10/25PAC column
(Whatman Inc., Clifton, New Jersey, U.S.A.) fitted with a
50 pi loop injector (Rheodyne, BerkeleyjCalifornia, U.S.A)
connected to a Dupont 848 Pump (Dupont Instruments,
Wilmington, Delaware, U.S.A.). In some experiments, the
column eluant was monitored for UV absorbing material
using a Cecil CE212 variable wavelength spectrophotometer
(Cecil Instruments, Cambridge, England). For PGB2, the
incident light beam was set at 280 nm and for the mono-
hydroxytetraenoic acid 12-HETE at 235 nm. On other
occasions when samples contained no chromophore, radio¬
active tracer was present and fractions of the column
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eluant were collected on a fixed time basis using an
Ultrorac collector (LKB Ltd., Stockholm, Sweden).
Scintillation counting of samples of these fractions
indicated the elution time of the radioactive material.
On occasions when the chromatographic efficiency of the
column had deteriorated, the column was cleaned by eluting
with chloroform/methanol (50/50) containing 0.1% acetic
acid. After normal use, the column was eluted with
methanol for a half-hour period.
Two solvent system were routinely used:
hexane/isopropanol (4/1) (HPLC 1)
hexane/isopropanol (10/1) + 0.1% acetic acid (HPLC 2)
The flow rate was set at 1 ml.min ^.
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2.6 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
The GC-MS data obtained in the subsequent sections was
obtained using a VG-Micromass 16-16F or a VG-Micromass
70-70F mass spectrometer. Pye 204 gas chromatographs were
coupled to each mass spectrometer by means of a single
stage glass separator. The gas chromatograph was
equipped with a spiral glass column (either 2 m or 3 m x
4 mm internal diameter) packed with 3% OV-1 on Supelcoport
100-120 mesh (Supelco Inc., Bellefonte, Pennsylvania,
U.S.A.).
Mixtures of fatty acid methyl esters were used as
retention standards. The retention times of the standards
were plotted on a logarithmic scale against the number of
carbon atoms of the esterified carboxylic acids (Berg-
strflm et al, 1963) and the graphs obtained were used to
convert observed retention times into carbon values. This
fatty acid mixture was also very useful in providing an
indication of the chromatographic efficiency of the column
and the sensitivity of the mass spectrometer prior to the
analysis of samples.
Typical mass spectrometer operating conditions were:
Separator temperature : 250°C
Ion source temperature : 220°C
Electron energy : 22-70 eV (dependent on instrument per¬
formance)
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Accelerating voltage : 4 kV
Mass spectra were recorded using a light beam oscillograph
(S.E. Labs (EMI) Ltd., Feltham, England). Normally, two
scans of each peak were recorded at differing amplifi¬
cations in order to obtain one spectrum with the base
peak on scale and, in addition, a second more sensitive
spectrum for the detection of low intensity, high mass ion
fragments.
The VG-Micromass 70-70F was used in the selected ion
monitoring mode with fixed magnet current and voltage
scanning. The exact mass measurements of the OV-1 phase
column bleed ion fragments (which v/ere initially deter¬
mined using perfluorokerosene as calibration standard)
were used for reference purposes. The mass spectrometer
was tuned to the required ion fragment for selected ion
monitoring by reference of its precise mass to the precise
mass of the nearest column bleed ion fragment and single
ion chromatograms were recorded on a multi-pen recorder
(Rikadenki, Mitsui Electronics (UK) Ltd.).
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2.7 LIQUID SCINTILLATION COUNTING
All radioactive samples were counted in a refrigerated
liquid scintillation counter (Nuclear Chicago Ltd., High
Wycombe, England). The scintillation fluid for monitoring
the column eluant of the liquid-gel chromatographic
separations was a 0.8% solution of 2,5-diphenyl^jaxazole
(Fisons Scintillation Reagents, Loughborough, England).
In other instances, 1 volume toluene:2 volumes PCS
(Amersham Corporation, Arlington Heights, Illinois, U.S.A)
was used.
Samples with the same quenching properties, for example,
chromatographic fractions, were compared as counts per
minute (CPM). In other cases, the CPM were converted to
disintegrations per minute (DPM) by the routine use of
the automatic external standard method which allowed the
percentage efficiency of each individual sample to be
calculated. All quantitative determinations were carried
out on the calculated DPM values.
Quantification of metabolites was determined by comparison
of the amount of radioactivity in each sample with the
initial amount of radioactivity added to incubates (this
was equivalent to a known amount of arachidonic acid).
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2.8 ULTRAVIOLET SPECTROSCOPY
Ultraviolet spectra were recorded with a Pye Unicam SP
800B Spectrophotometer (Pye Unicam Ltd., Cambridge,
England) in a 3.5 ml silica glass cell, path length 1 cm.
Spectra of solutions of samples were obtained against
their solvent in the reference cell.
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2.9 PHARMACOLOGICAL EXPERIMENTAL METHODS
1. Platelet Aggregation
Platelet rich plasma (PRP) was prepared as described
previously (Section 2.2) and kept at room tempera¬
ture. Platelet aggregation was monitored photo¬
metrically at 37°C using a Born Aggregometer (H.
Upchurch & Co. Ltd., Leicester, England (Born, 1962)
connected to a Servoscribe pen recorder (Belmont
Instruments, Glasgow). 0.5 ml of PRT and 0.5 ml of
0.9% (w/v) sodium chloride solution were added to
silanised glass tubes, placed in the aggregometer
and stirred for three minutes which allowed the
platelet suspension to reach the required tempera¬
ture of 37°C.
The aggregation response, which resulted in an in¬
crease in light transmittance, was monitored follo¬
wing the addition of different doses of arachidonic
acid or adenosine diphosphate (ADP) and hence a dose
was determined for each compound which was slightly
greater than the minimum dose required to induce
irreversible aggregation. This dose was used in sub¬
sequent testing of potential inhibitors. These were
added to the platelet suspension in saline or in a
small volume of methanol (< 3%, v/v, this volume was
shown to have no direct effect on the aggregation
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response) and pre-incubated for five minutes at 37°C
before the addition of the arachidonic acid or ADP.
After each experiment, the glass tubes were washed,
re-silanised using a 5% solution of dimethylchloro-
silane in toluene and rinsed with methanol.
2. Prostaglandin I2 Production
The method of preparation and assay of prostaglandin
I2 was similar to that described by Bunting et al
(Bunting, Gryglewski, Moncada and Vane, 1976a).
Prostaglandin I2 was produced by incubating arachi¬
donic acid with aortic rings and monitored, by its
powerful anti-aggregating effects on platelet aggre¬
gation induced by ADP, using a Born Aggregometer as
described in the previous sub-section.
The PRP was treated with indomethacin (10 jj.14) to
negate any potential effects of unreacted arachi¬
donic acid in the aortic ring incubate samples. A
dose response curve of the platelets to ADP was pre¬
pared and hence a dose slightly greater than the
minimum dose required to induce irreversible aggre¬
gation was determined. This dose was used in the
subsequent determinations.
An abdominal aorta was obtained from a freshly sac¬
rificed rabbit and connective tissue disconnected.
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The strip of aorta was weighed and then stored on ice
on a piece of cotton wool soaked in tris (hydroxvirethyl)-
amine-FCl buffer (0.05M, pH 7.5). Aortic rings
(approximately 10 mg) were cut from the strip of
tissue as required, washed six times with tris
buffer and incubated with arachidonic acid (30 (J.M) in
0.2 ml tris buffer for three minutes at room tempe¬
rature. Aliquots of incubates were immediately
transferred into the platelet suspension (already at
37°C in the aggregometer) and incubated with the
platelets for one minute prior to the addition of
APD. The anti-aggregatory properties of the aortic
ring incubates (which were an indication of PGI2
synthesised) were therefore determined.
A control response of the platelets to ADP was deter¬
mined after testing a set of three aortic ring in¬
cubates in order to check that addition of ADP to the
platelets still resulted in a similar aggregation
response. If the platelets had become less sensitive
then the dose of ADP was increased until a response
similar to that obtained previously was attained.
The inhibitory effect of a compound on PGI2 synthesis
was tested by soaking the aortic ring in 0.2 ml of
tris buffer containing the compound for 5 min at 0°C,
decanting the buffer, adding a further 0.2 ml buffer
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acid and monitoring the PGI2 produced as described
above. Inhibition of synthesis resulted in less
"anti-aggregatory activity" in the aortic ring in¬
cubate and when this activity was monitored using
the platelet system, this resulted in an aggregation
response when ADP was added. When the inhibitory
effect of indomethacin was tested, an additional
amount of indomethacin was added to the ADP control
response to compensate for the potential effect of
the amount transferred from the aortic ring incubate.
This was not necessary for the other compounds tested
as they had been shown to have no direct effect on
the ADP aggregation response.
3. Tissue Preparations
A rat fundus and rabbit aorta were obtained from
freshly sacrificed animals and prepared for bioassay
as described previously (Staff, University of Edin¬
burgh) . In both cases, the tissues were attached
(under tension [3 g fundus4 g aorta]) by threads
to smooth muscle isometric transducers which were
connected to a Grass polygraph multi-channel pen
recorder (Grass Instrument Co., Massachussettes,
U.S.A.) and superfused at 7.5 ml.min ^ with Krebs
solution at 37°C which contained a mixture of non-
prostaglandin antagonists (Table 2.3). This in¬
creased the specificity of the assay tissues to
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compounds acting on prostaglandin receptors. Both
tissues were superfused for approximately 1 h before
use. Thereafter, a 10 min dose cycle was adopted
when either standard prostaglandins, prostaglandin
analogues or test compounds were injected (in Krebs,
saline or saline containing a small amount of sodium
bicarbonate) onto the tissues.
A guinea pig ileum was used as an assay tissue and
was prepared for bioassay as described previously
(Staff, University of Edinburgh). It was attached
under 0.5 g tension by threads to an isotonic trans¬
ducer connected to a Grass Polygraph in an 8 ml organ
bath in Tyrode. The tissue was washed repeatedly for
the first 30 min and thereafter a 4 min dose cycle
was adopted when either acetylcholine, a standard
prostaglandin or test compound were injected in
saline (or saline containing a small amount of sodium
bicarbonate) into the organ bath. The compound was
allowed a 30 sec contact time, after which the
tissue was washed for 1.5 min and left to stabilise
for a further 2 min.
4. Chemotaxis
Preparation of Polymorphonuclear Leukocyte (PMNL)
Suspensions
Rabbit peritoneal PMNL suspensions were obtained by
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the technique of Hirsch and Church (1960). Dutch
rabbits (2-3 kg) were used with intervals of 7 to
10 days between leukocyte collections from the same
animal. 200 ml of 0.1% (w/v) oyster glycogen
(Calbiochem, San Diego, California, U.S.A.) in 0.9%
(w/v) sterile sodium chloride solution (saline) was
administered by intraperitoneal injection. Four
hours later, the peritoneal cavity was washed out
with 100 ml TC199 (Gibco-Biocult, Glasgow, Scotland)
fortified with Earles salts, 25 mM HEPES buffer (N-2
hydroxyethyl-piperazine-N-ethane sulphonic acid),
benzyl penicillin (100 units.ml "*j and streptomycin
(100 p.g.ml "*") . The cell suspension was collected in
silanised centrifuge tubes containing heparin
(5 units.ml ^ final volume).
Differential leukocyte counts showed the PMNL to be
the predominant species. Occasionally, PMNL via¬
bility (measured by trypan blue exclusion) fell below
95% or the leukocyte suspensions were contaminated
with erythrocytes. These suspensions were discarded.
Suspensions containing 5 x 10^ PMNL.ml ^ were pre¬
pared by centrifugation (52 x g for 10 min) of a
known volume containing the appropriate number of
cells. The cell pellet was suspended in the correct
volume of fortified TC199 containing bovine serum














Figure 2.4 Modified Boyden chamber used in chemotaxis
experiments
Measurement of Chemotaxis
Disposable polystyrene chemotactic chambers (Adaps
Inc., Dedham, Massachussettes, U.S.A.) based on the
principle of Boyden (1962) and mixed cellulose
acetate/cellulose nitrate filters with 8.0 (am pore
size (Me'mbrane SCVJP 01300 , Millipore S.A., Molsheim,
France) were used for the measurement of chemotaxis.
The filter was cemented to the upper compartment of
the chemotactic chamber (M.F. Cement, Millipore Corp.,
Bedford>Massachussettes, U.S.A.).
All compounds to be investigated were prepared in
fortified TC199 containing BSA (100 jag.ml ^) 2 h
before required. Test and control chambers were
prepared for each compound. The test chamber con¬
tained test solution (1.0 ml) in the lower compart¬
ment and 0.9 ml PMNL suspension plus 0.1 ml fortified
TC199 (+ BSA) in the upper chamber. Control cham¬
bers contained test solution (1.0 ml) in the lower
compartment and 0.9 ml PMNL suspension plus 0.1 ml
fortified TC199 (+ BSA) containing the same amount
of test material in the upper compartment (Figure
2.4). Chambers containing no test materials were
prepared for each experiment to provide background
values of leukocyte migration. The chambers were































The filter was then removed, stained according to the
procedure in Table 2.4 and mounted on a microscope
slide with DPX mountant (BDH Chemicals Ltd., Poole,
England). The lower surface of the filter was ex¬
amined microscopically and the mean number of PMNL
from five randomly selected high power fields (ob¬
jective x40) was calculated to give an indication of
the chemotactic index.
An increase in cell count in comparison to the back¬
ground when the compound was present in equal concen¬
tration on both sides of the chamber (control cham¬
ber) gives an indication of chemokinetic activity.
Similarly, an increase in cell count in the test
chamber in comparison to the control chamber gives
an indication that the substance is exerting a
chemotactic influence.
Equilibration studies involved setting up six identi¬
cal chambers containing PGF2 a (1 pg) with 3H-PGF2a
as tracer in the lower part of the chamber and the
PMNL suspension in the upper part of the chamber.
At regular intervals (1, 2 and 3 h), two chambers
were removed from the incubator and 0.5 ml sampled
from each side of each of the chambers. The amount
of radioactivity in each of the samples was deter¬
mined by liquid scintillation counting and hence the
percentage of radioactivity in each part of the
chamber was calculated.
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5 . Blood Pressure Experiments
Two male cats (weight 2.8 and 3.0 kg) were initially
anaesthetised with sodium phenobarbitone (40 mg.kg
and a maintenance infusion was made into the internal
jugular vein (36 mg.h "*") . Blood pressure was re¬
corded from the common carotid artery and the heart
rate was recorded on a tachometer triggered from the
blood pressure pulse. Drugs were infused intra¬
venously into the femoral vein in saline (or saline
containing a small amount of sodium bicarbonate). On
one occasion after the cat was killed, its blood was
collected and PRP and washed platelets prepared and
incubated in the normal manner (Sections 2.2 and 2.3)




THE INCUBATION OF ARACHIDONIC ACID
WITH WASHED BLOOD PLATELETS WITH THE DETECTION





Thromboxane B2 was required in the laboratory as a refe-
renace standard for a proposed GC-MS investigation of a
number of biological samples and was not, at the time,
available from the Upjohn Company. Washed blood platelets
incubated with arachidonic acid are reported to produce
thromboxane B2 as a major product (Hamberg and Samuelsson,
1974a) and therefore it was decided to attempt the prepa¬
ration of thromboxane B2 by this method.
Incubation of arachidonic acid with washed horse platelets
and subsequently washed human platelets revealed the pre¬
sence of novel arachidonic acid metabolites. Purification
of the incubation extracts by liquid-gel partition chroma¬
tography, followed by a GC-MS examination of a number of
derivatives of selected chromatographic zones provided
structural evidence for stereoisomers of two trihydroxy
acids - 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid (8,-
11,12-THETA) and 8,9,12-trihydroxy-5,10,14-eicosatrienoic
acid (8,9,12-THETA), termed THETA collectively. The
structural evidence obtained by GC-MS and the factors






Figure 3.1 Gas chromatogram of 33% aqueous ethanol extract
from a washed horse platelet incubate sample
(Me/TMSJ
3.2 THE INITIAL EXAMINATION OF PLATELET INCUEATES
BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY
Examination by GC-MS of the methyl ester/trimethylsilyl
ether (Me/TMS) derivatives of the 33% aqueous ethanol ex¬
tracts from washed horse platelet incubates on three
separate occasions indicated that only very small amounts
of thromboxane B2 were present. Peak 4 in the chromatogram
(Figure 3.1) was identified as thromboxane B2 (Me/TMS) by
comparison of its retention time (carbon value 24.6) and
mass spectrum with published data (Hamberg, Svensson and
Samuelsson, 1975j Smith, Harland and Brooks, 1977). It
was noted that the horse platelet rich plasma did not
aggregate to arachidonic acid.
Incubation of horse platelets with arachidonic acid was
clearly not a satisfactory method for the preparation of
thromboxane B2. The very small amounts of thromboxane B2
identified in the horse platelet incubates together with
the observation that the horse platelet rich plasma did
not aggregate to arachidonic acid raised the following
possibilities:
a) the horse platelets were deficient in the prosta¬
glandin cyclo-oxygenase enzyme
b) the horse platelets were deficient in the thromboxane
synthetase enzyme
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c) the animals had received drug treatment before their
death,or diet which resulted in an inhibition of
either the prostaglandin cyclo-oxygenase and/or
thromboxane synthetase enzymes
Deficiency of thromboxane synthetase seemed unlikely in
view of the fact that horse platelet microsomes have been
used for the preparation of thromboxanes from prosta¬
glandin endoperoxides (Needleman et al, 1976) and are
known to be good source of thromboxane synthetase. In
contrast, there were no previous reports of using horse
platelets to prepare thromboxanes from arachidonic acid
and in light of the above observations, it seemed a possi¬
bility that these platelets might be deficient in the
prostaglandin cyclo-oxygenase enzyme. No information was
available concerning drug treatment of the animals.
The other GC peaks in the chromatogram of the horse plate¬
let incubate sample were examined. Interest became cen¬
tred on a major GC peak (peak 3, Figure 3.1) which had a
slightly shorter chromatographic retention time (carbon
value 23.6 - 23.8) than thromboxane B2. GC-MS evidence
indicated that this same material was formed when washed
human platelets were incubated with arachidonic acid. In
the case of the human platelet incubates, the relative
amounts of thromboxane B2 and this unidentified material
varied considerably. Sometimes, the thromboxane B2 was
present in larger amounts, in others,the unidentified
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Fraction (1 min)
Figure 3.2 HPLC radio-chromatogram of unidentified material and PGF2a
both as their methyl ester derivatives
material. This was in contrast to the horse platelet
incubates where the unidentified material was consistently
present in considerably greater amounts than thromboxane
B 2 •
The formation of this unidentified material was not inhi¬
bited by the prostaglandin cyclo-oxygenase inhibitor indo-
methacin (10 pM), which inhibited the thromboxane B2 for¬
mation, and indicated that the unknown was not a product
of the prostaglandin cyclo-oxygenase pathway. However,
its formation was inhibited by heating the platelets at
60°C for 20 min prior to incubation or by pre-incubation
of the platelets with eicosa-5,8,11,14-tetraynoic acid
(ETYA) (10 pM), an inhibitor of both prostaglandin cyclo-
oxygenase and platelet and soyabean lipoxygenase enzymes
(Downing, Barve, Gunstone, Jacosberg and Lie Ken Jie,
1972j Hamberg and Samuelsson, 1974a).
Initially, purification of the methyl ester of the horse
platelet incubation extracts was achieved by liquid-gel
partition chromatography (solvent system LGC 1) and high
peformance liquid chromatography (solvent system HPLC 1).
This afforded a single zone of radioactivity, slightly
less polar than PGF2a (Figure 3.2) containing the uniden¬
tified material of interest. A variety of derivatives
were prepared and examined by GC-MS. The principal infor¬
mation derived from each is summarised in Table 3.1.
Incubation of dihomo-y-linolenic acid with washed human
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TABLE 3.1




Main information obtained from mass spectra
Methyl ester/trimethylsilyl
ether (Me/TMS) 23.6 23.8
Indicated a compound with molecular weight
of 584. The base peak at m/e 213 and the
large ion at 243 indicated the most likely





Oximation had no effect on the material and





M^e 213 still the base peak. The ion
fragment at rcfye 243 was shifted to m"Ve 257
and indicated that the ion fragment at mye
243 in the Me/TMS contained the ester group
Similarly the other ion fragments in the
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Indicated that three double bonds were pre¬






All the material formed a boronate which
indicated that a 1,2 or 1,3 diol was pre¬
sent in the material. Large ions were
present at m~|/e 215 and 245.
Analogous material from di-
homo-y-linolenic acid in¬
cubate (Me/TMS) 23.9 24.1
Large ion fragments at ni^e 213 and 245
indicated that the ion fragment at rrfye 24 3
in the arachidonic acid incubate Me/TMS
spectrum contained the 5,6 double bond




Figure 3.3 The most likely structures of the unidentified
material
platelets resulted in the formation of an analogous
material which provided additional structural information.
The unidentified material showed no diene absorption in
the ultraviolet region (100 (ig.ml ^ in methanol) which
indicated that no conjugated double bonds were present.
In all cases, the chromatographic peak shape of the deri-
vatised material was not symmetrical (for example, peak 3
in Figure 3.1) and indicated that two partially resolved
components were present. Mass spectra obtained from these
partially resolved peaks at the carbon values indicated
in Table 3.1 were very similar. Selected ion monitoring
of the major ion fragments in the spectra demonstrated that
they followed the same chromatographic profile as the total
ion chromatogram and suggested that isomers of this mate¬
rial were present. It was noteworthy that since the par¬
tially resolved peaks were still present after hydrogenation
they were not attributable to geometrical double bond iso¬
mers of the material.
All the evidence was consistent with a C20 fatty acid
containing three double bonds and three hydroxyl groups.
The Me/TMS, Et/TMS and Me/H2/TMS derivatives indicated
that the two most likely structures were with hydroxyl
groups in the C-8, C-ll and C-12 or C-8, C-9 and C-12
positions and that both were probably present (Figure 3.3).
Following examination of the spectra of the Me/H2/n-BuB/










Figure 3.4 Proposed fragmentation of Me/n-BuB/TI!S derivative
trihydroxy acids were present since large ions were pre¬
sent at m+/e 215 and 245. These ion fragments were assig¬
ned as arising from the cleavage beside the only remaining
TMS group in this derivative (Figure 3.4). Additional
evidence for the presence of both trihydroxy acids was
provided by the observation that the ratio of the ion
fragments at ai+/e 213 and 243 in the Me/TMS spectra in
different platelet incubates was not constant. It would
be expected that cleavage would occur preferentially
between the vicinal TMS groups (Capulla and Zorzut, 1968)j
thus the ion fragment at m+/e 213 would arise predominan¬
tly from the 8,11,12-compound and the ion fragment at m+/e
243 from the 8,9,12-compound (Figure 3.5). Therefore, if
differing relative amounts of the two trihydroxy acids
were formed in different incubations, the ratio of these
two ion fragments would be expected to vary.
However, the presence of two positional isomers did not
appear to account for the partially resolved gas chromato¬
graphic peaks. Selected ion monitoring of ions which were
proposed to arise from different positional isomers, for
example, the ion fragments at m+/e 213 and 243 in the Me/
TMS spectrum and the ion fragments at in+/e 215 and 24 5 in
the Me/H2/n-BuB/TMS spectrum indicated that these ion frag¬
ments followed virtually identical chromatographic pro¬









Figure 3.5 Proposed fragmentation of Me/TMS derivative
Evidence at this stage indicated that two positional tri-
hydroxy trienoic acids (termed THETA) were formed and that
hydroxyl stereoisomers of each were present. The following
sub-section describes the separation of these positional
isomers by liquid-gel partition chromatography. As a re¬
sult, a simplified structure elucidation of the components
became possible. Full mass spectral evidence is presented




Figure 3.6 LGC radio-chromatogram of 33% aqueous ethanol extract
from washed human platelet incubate sample
3.3 SEPARATION OF THE POSITIONAL ISOMERS
OF THE TRIHYDROXY ACIDS BY LIQUID-GEL
CHROMATOGRAPHY AND EXAMINATION OF A VARIETY OF
DERIVATIVES OF EACH BY GAS CHROMATOGRAPHY-
MASS SPECTROMETRY
Supplies of horse blood were not readily available and it
was found that three day old human platelet concentrate
obtained from the Blood Transfusion Service, Edin¬
burgh Royal Infirmary (which was readily available)
contained sufficient synthetic activity for the prepa¬
ration of THETA. This concentrate was used for the pre¬
paration of THETA on several occasions as suitably large
numbers of platelets were available, which allowed large
scale incubations and hence the isolation of greater
amounts of material than could be obtained using smaller
volumes of fresh human blood donated by individual volun¬
teers .
In order to attempt the separation of the two postulated
positional isomers, the free acid from the incubation
extract was subjected to liquid-gel partition chromato¬
graphy (solvent system LGC 2). Figure 3.6 shows a typical
chromatographic separation obtained from a human platelet
incubate (using three day old platelet concentrate from
the Blood Transfusion Service).
Examination of Zone V by GC-MS as the Me/TMS derivative
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Figure 3.8 Mass spectrum of 8,11,12-THETA (Me/TMS)
(Figure 3.7). The mass spectrum of peak 3 (carbon value
24.6) corresponded to thromboxane B2. The mass spectrum
was very similar to published data (ref. Hamberg, Svensson
and Samuelsson, 1975 j Smith, Harland and Brooks, 1977)
and was later shown to be identical with a thromboxane B2
standard donated in the course of this study by the Upjohn
Company. The other major GC peaks (peaks 1 and 2) were
only partially resolved (carbon values 23.6 and 23.8) and
mass spectra taken at these carbon values were very simi¬
lar (Figure 3.8). These spectra were noticably different
from spectra taken at the same carbon values in a sample
of the material which had not been subjected to the
chromatographic separation. The immediately apparent
difference was the change in relative abundance of the
ion fragments at m+/e 213 and 243 as the ion fragment at
m+/e 243 was of much lower relative abundance in the LGC
chromatographed sample. This indicated that separation
of the proposed positional isomers had occurred. The
spectra were consistent with isomers of a C20 fatty acid
methyl ester containing three double bonds and three TMS
groups at the C-8, C-ll and C-12 positions. This com¬
pound was named 8,11,12-THETA standing for trihydrcxy-
eicosatrienoic acid.
Evidence for the isomers was provided by selected ion
monitoring of the ion fragments at m+/e 213 and 243 -
their chromatographic profile was identical both to each
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Figure 3.10 Mass spectrum of 8,9,12-THETA (Me/TMS)
partially resolved components. The base peak at m+/e 213
was interpreted to arise from the preferential cleavage
between the vicinal TMS groups (similar to that described
by Capulla and Zorzut, 1968) , whereas, the very much less
intense ion fragment at m+/e 243 was interpreted to arise
from, the less preferred cleavage at a TMS group allylic to
a double bond. Most of the ion fragments were interpreted
as resulting from cleavages at either side of the TMS
groups or involving losses of or from. TMS groups or loss
of the methoxy moeity from the ester (the Et/TMS spectrum
was consistent with all the assignments in Figure 3.8).
An interesting exception was the fairly intense ion frag¬
ment at m+/e 444 in the Me/TMS spectrum, which was shifted
to m.+/e 458 in the Et/TMS spectrum. A possible inter¬
pretation of these ions was that they resulted from a
re-arrangement which involved the migration of the vicinal
TMS group in the C-12 position and resulted in the loss of
an unsaturated aldehyde (CH3-(CH2)4-CH=CH-CH2-CHO). This
re-arrangement has been observed in the spectrum of 9,1C-
bis(TMS)-methyl stearate (Odham and Stenhagen, 1972).
GC-MS examination of Zone IV of the liquid-gel chromato¬
graphic separation as the Me/TMS derivative indicated that
two partially resolved GC peaks (carbon values 23.6 and
23.8) were present (Figure 3.9). As above, the mass
spectrometric analysis indicated that the partially
resolved chromatographic peaks were isomers with very














































Figure 3.12 Mass spectrum of 8,9,12-THETA (Me/H2/TMS)
carbon value
24. 7






Figure 3.13 Selected ion chromatograms at m+/e 215 and 245 of 8,11,12-
THETA and 8,9,12-THETA (both Me/H2/TMS)
with a C20 fatty acid methyl ester containing three
double bonds and three TMS groups at the C-8, C-9 and
C-12 positions. This compound was named 8,9,12-THETA.
The base peak at m+/e 243 was interpreted as arising from
cleavage between the vicinal TMS groups (as in the case of
8,11,12-THETA) and it was noted that only a very small
ion fragment at m+/e 213 was present. The Et/TMS spec¬
trum was consistent with all assignments.
The above evidence indicated that the two trihydroxy acids
which had been postulated as products in sub-section 3.2
had been completely resolved from each other by the
liquid-gel chromatographic separation. Further work was
undertaken with the aim of confirming the structure of
each of the trihydroxy acids by preparing a variety of
derivatives for GC-MS analysis.
Following methylation, hydrogenation and TMS ether for¬
mation, both compounds still showed two partially resolved
GC peaks (carbon values 24.4 and 24.7). The mass spectra
of both compounds taken at these carbon values indicated
that the partially resolved GC peaks were isomers and the
spectra of both compounds confirmed the presence of three
double bonds in the original materials. Mass spectra of
the 8,11,12-THETA isomers and the 8,9,12-THETA isomers are
shown in Figures 3.11 and 3.12 respectively. Selected ion
monitoring of the ion fragments at m+/e 245 and 215 of
both compounds (Figure 3.13) supported the existence of




































































Figure 3.15 Mass spectrum of 8,9,12-THETA (Me/H2/n-BuB/TMS)
isomers as removal of the double bonds had ruled out the
possibility that the observed isomers were geometrical
double bond isomers.
The hydrogenated forms of both compounds formed an n-butyl
boronate/mono-TMS derivative which supported the presence
of vicinal hydroxyl groups. Two partially resolved GC
peaks were observed for both compounds (carbon values
26.0 and 26.2). Their mass spectra (Figures 3.14 and
3.15) indicated that the partially resolved chromatographic
peaks were isomers which was supported by selected ion
monitoring of the ion fragments at m.+/e 215 and 245. The
ion fragment at m+/e 245 was the base peak in the mass
spectrum of the 8 ,11,12-THETA and the ion fragment at n+/e
215 was the base peak in the mass spectrum of 8,9,12-THETA.
These ion fragments were mutually exclusive for each
positional isomer. Assignment of the ion fragments in
these spectra was assisted by the boron isotope pattern
(1°B 20%. 1XB 80%). The formation of the hydrogenated/
boronated derivatives very effectively altered the posi¬
tion of preferential cleavage in these compounds from the
vicinal hydroxyl groups (in the Me/TMS, Et/TMS, Me/H2 /TMS
spectra) to the third remaining hydroxyl group and hence
confirmed the position of this third hydroxyl group.
In summary, all GC-MS evidence supported the structure of
two positional trihydroxy acids: 8,11,12-trihydroxy-5,9,14-
eicosatrienoic acid (8,11,12-THETA) and 8,9,12-trihydroxy-
5,10,14-eicosatrienoic acid (8,9,12-THETA). GC-MS
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evidence indicated that hydraxyl stereoisomers of both
these positional isomers were present.
Further work is required to establish the configurations
of the hydroxyl groups and double bonds. The reader is
referred to the concluding remarks in this section for a
consideration of the number of possible hydroxyl stereo¬
isomers present and the configuration of the double bonds.
It is noteworthy that THETA solutions stored at -20°C in
methanol were stable for several months.
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A - monitor THETA B - monitor thromboxane B2 amplification constant
throughout
Figure 3.16 Selected ion chromatogram showing relative amounts of THETA
and thromboxane B2 in 5 min and 30 min incubation samples
(Me/TMS)
3.4 FACTORS AFFECTING THE FORMATION OF
THE TRIHYDROXY ACIDS
It was demonstrated that in addition to washed platelets
from horse and human, washed blood platelets from dog, cat
and rabbit incubated with arachidonic acid produced THETA.
Drs. Kerry, Poyser and Wilson detected THETA following
incubation of arachidonic acid with sheep spleen and
sheep uteri homogenates (Jones, Kerry, Poyser, Walker and
Wilson, 1979). As reported earlier, the formation of
these trihydroxy acids was not inhibited by the prosta¬
glandin cyclo-oxygenase inhibitor indomethacin (10 fiM)
but was almost completely abolished by the tetraynoic acid,
ETYA (10 pM) which is an inhibitor of both the prosta¬
glandin cyclo-oxygenase and platelet lipoxygenase enzymes.
It was interesting to observe that considerably more THETA
was present after a 30 minute incubation compared with a
5 minute incubation period (Figure 3.16). A similar
observation was made by Nugteren concerning 12-HETE
synthesis by platelets. In contrast, it was observed that
no additional thromboxane B2 or HHT synthesis occurred
after 5 minutes (Nugteren, 1977).
The substrate concentration of arachidonic acid was a
crucial factor in the formation of the trihydroxy acids.
At low concentrations of arachidonic acid, thromboxane B2
was produced but the amounts of THETA were virtually
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Thromboxane B2




























A - monitor THETA B - monitor thromboxane B2 amplification constant
throughout
Figure 3.17 Selected ion chromatograms showing increased THETA production
with increased substrate concentration in incubates (Me/TMS)
from a washed human sample divided into four equal parts.
Thromboxane B2
THETA














Figure 3.18 Selected ion chromatograms showing that THETA production
was more pronounced in washed platelet than in platelet
rich plasma incubate samples (Me/TMS). The reader is
referred to Section 2.3 for full experimental details
_A—^56_
_A_ 225
non-detectable. As the concentration of arachidonic acid
was increased, the relative amount of THETA compared to
thromboxane Bz increased dramatically (Figure 3.17).
The formation of THETA was more pronounced in washed plate¬
lets than in platelet rich plasma incubates (Figure 3.18).
This was probably accounted for by the lower amounts of
arachidonic acid available to the platelets in the plate¬
let rich plasma as considerable protein binding of ara¬
chidonic acid occurs (Nugteren, 1977; Smith, Ingerman and
Silver, 1977). This observation may therefore be related
to the previous observation that THETA synthesis was more
significant at higher arachidonic acid concentrations.
Shortly after the isolation and structural determination
of THETA was reported from our laboratory (Jones, Kerry,
Poyser, Walker and Wilson, 1978) , Bryant and Bailey re¬
ported the isolation of the same compounds from washed
platelet incubations (Bryant and Bailey, 1979). These
workers deduced that 8,11,12-THETA was definitely present
in their samples and that 8,9,12-THETA might also be pre¬
sent. No attempt was made to separate the positional
isomers. They reported that addition of glucose (2 mg.
ml *) to the platelet incubation buffer totally elimi¬
nated THETA production. This effect was explained by the
glucose enhancing the level of reduced glutathione in the
platelets which caused a lowering of the level of 12-HPETE
by promoting its conversion into 12-HETE. Attempts to
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confirm these results in this study, at glucose concen¬
trations of 2 and 10 mg.ml / did not result in the re¬
ported inhibition. The exact experimental detail was not
provided in their publication and so differences in pro¬




Figure 3.19 Proposed mechanism of THETA formation
3.5 CONCLUDING REMARKS
Consideration was given to the mechanism of THETA forma¬
tion. The formation of THETA did not occur by the pros¬
taglandin cyclo-oxygenase pathway and it seemed likely
that the trihydroxy acids were products of the platelet
lipoxygenase pathway as ETYA inhibited both 12-HETE and
THETA production. A possible mechanism involved further
transformation of 12-HPETE via an epoxy-hvdroxy inter¬
mediate (Figure 3.19). Hydrolytic ring opening of such
an epoxide intermediate at the positions indicated in the
figure would result in the formation of the two hydroxy
acids. It was of interest to note that 9-hydroxy-12,13-
epoxy-10-octadecadenoic acid has been reported to be
converted into a mixture of 9,10,13-trihydroxy-l1-octa-
decenoic acid and 9,12,13-trihydrcxy-10-octadecenoic acid
in aqueous ethanol (Hamberg, personal communication).
After consideration of the results of the experiment with
differing arachidonic acid substrate concentrations, it
seems likely that THETA formation occurs during high
rates of 12-HPETE synthesis.
Several epoxy-hydroxy acids have been proposed and deter¬
mined as intermediates resulting from transformations
involving hydroperoxides in the synthesis of trihydroxy
fatty acids in plant lipoxygenase systems (Graveland,
1970, 1973) Arens and Grosch, 1974) for reviews: Gardener,

















[ - considered unlikely
Figure 3.20 Possible hydroxyl stereoisomers of 8,11,12-THETA
and 8,9,12-THETA
bations of linoleic acid with flour water suspensions and
doughs, Graveland (1970) isolated trihydroxy acids in
both cases, but only in the latter case isolated the inter¬
mediate epoxy-hydroxy compound. He stated that, in the
suspension, hydrolysis of the intermediate took place so
rapidly it was impossible to detect. Trihydroxy acids
have also been detected as products in non-enzymic
reactions, for example, following treatment of linoleic
acid hydroperoxide with ferric ions and cysteine (Gardner,
Kleiman and V7eisleder, 1974).
Assuming the proposed mechanism of THETA formation then
several stereoisomers of both 8,11,12-THETA and 8,9,12-
THETA were expected to be present (Figure 3.20). From a
consideration of the literature, it was considered likely
that the 9,10-double bond in 8,11,12-THETA and the 10,11-
double bond in 8,9,12-THETA were trans, although from the
evidence obtained, it was not possible to determine
whether the configurations were trans or cis and the
possibility that both were present could not be discounted.
The 5,6- and 14,15-double bonds were considered likely to
have remained cis.
In order to possibly detect and identify the epoxy-
hydroxy or a similar intermediate, it was decided to
investigate the less polar peaks obtained from the liquid-
gel chromatographic separation. This work is described
in section 4 of this thesis. It was also of interest to
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determine whether or not 8,11,12-THETA and 8,9,12-THETA
possessed any pharmacological activity and a number of
tests were performed which are described in Section 5.
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SECTION 4
THE INCUBATION OF ARACHIDONIC ACID
WITH WASHED BLOOD PLATELETS WITH THE





During attempts to identify the proposed THETA inter¬
mediate (8-hydroxy-ll,12-epoxy-5,9,14-eicosatrienoic acid)
an analogous compound was detected. Structural examination
of various derivatives of this compound by GC-MS indicated
its structure as 1O-hydroxy-11,12-epoxy-5,8,14-eicosatri¬
enoic acid and not the proposed THETA intermediate. Iso¬
mers of this compound were shown to be present and were
resolved by high performance liquid chromatography.
Other products of the platelet incubation extract were
identified by GC-MS and included the monohydroxytetraenoic
acid 12-HETE, the C17 monohydroxy acid HHT and another
unidentified compound which co-chromatographed on the





















Figure 4.1 Mass spectrum of 12-HETE (Me/TMS)
4.2 THE EXAMINATION OF THE TWO LEAST POLAR
LIQUID-GEL CHROMATOGRAPHIC ZONES AND THE
DETECTION AND EXAMINATION BY GAS CHROMATOGRAPHY-
MASS SPECTROMETRY OF A MOLECULE ANALOGOUS TO
THE PROPOSED THETA INTERMEDIATE
Zone I of the Liquid-Gel Chromatographic Separation
The monohydroxytetraenoic acid 12-HETE was identified in
Zone I of the liquid-gel chromatographic separation of the
platelet incubate (Figure 3.6). The stability of the Me/
TMS derivative of this material to gas chromatography was
found to depend markedly on the chromatographic conditions.
On many occasions, a broad irregularly shaped GC peak with
higher carbon value (22.0 - 23.1) than that previously re¬
ported for 12-HETE (Me/TMS) (carbon value 21.3) was de¬
tected and was attributed to the "on-column" decomposition
of the 12-HETE derivative. Decomposition was demonstrated
by making repeat injections of the same sample under
varying chromatographic conditions (injector/oven tempera¬
tures and column length/condition). Mass spectra of the
higher carbon value GC peak contained a characteristic
intense ion fragment at m+/e 213. Although on many
occasions the chromatography of the Me/TMS derivative was
not totally satisfactory, it was considered adequate for
qualitative identification. Under optimised chromato¬
graphic conditions, satisfactory chromatography of this
derivative was achieved. Peak 1 (Figure 3.1) in the













Figure 4.3 Mass spectrum of major peak from LGC Zone II
(Me/TMS)
let incubate had an identical carbon value (21.3) as that
reported for 12-HETE (Me/TMS) and its mass spectrum
(Figure 4.1) was very similar to published data (Hamberg
and Samuelsson, 1974a).
Solutions of 12-HETE stored at -20°C in methanol were not
stable. 12-HETE has a IT/ absorbing chromophore (attribu¬
table to the diene) which shows an absorbance maximum at
235 nm in methanol. Significant loss of this chromophore
occurred after two to three weeks storage. Similar storage
problems of 12-HETE have been reported by Turner and the
Upjohn Company (Turner and Lynn, 1978).
Zone II of the Liquid-Gel Chromatographic Separation
Examination by GC-MS of the more polar shoulder on the 12-
HETE peak of the liquid-gel chromatographic separation
(Zone II, Figure 3.6) as the Me/TMS derivative indicated a
single major GC peak (carbon value 22.05) (Figure 4.2) with
a mass spectrum analogous to the proposed THETA inter¬
mediate. The mass spectrum (Figure 4.3) indicated a com¬
pound with a molecular weight of m+/e 422 and was consis¬
tent with a C20 fatty acid methyl ester containing three
double bonds, one TMS group and one keto or epoxv oxygen.
The material did not form an oxime which indicated the
absence of a keto group. The mass spectrum of the Et/TMS
derivative (carbon value 22.6) was consistent with all the
assignments in Figure 4.3 and contained a base peak at m+/e
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283. The Me/TMS and Et/TMS spectra indicated that the
most likely position of the TMS group was in the C-10
position but did not rule out the possibility of a TMS
group in the C-8 position. It was interesting to note
that a C18 analogue with a TMS group adjacent to an epoxide
showed a very similar fragmentation pattern (Hamberg and
Gotthammar, 1973). In contrast, mass spectra of C18 y-
hydroxy epoxides, which were comparable to the proposed
THETA intermediate, showed marked differences (Graveland,
1970) Hamberg, 1975). Notably cleavage was observed
adjacent to the TMS group. The corresponding cleavage in
the proposed THETA intermediate would result in an ion
fragment in the Me/TMS spectrum at m+/e 243 - this ion
was totally absent from the spectrum of the platelet pro¬
duct. The ion fragments at m+/e 282/281 in the Me/TMS
spectrum of the platelet product were interpreted as re¬
sulting from the transannular cleavage of the epoxide
which occurs with and without proton transfer (BudzikiewiczL,
Djerassi and Williams, 1967; Alpin and Coles, 1967).
This compound was named EPHETA standing for epoxyhydroxy-
eicosatrienoic acid. Its formation was not inhibited by
indomethacin (10 jaM) but was inhibited by ETYA (10 pM) .
Further work was undertaken with the aim of establishing
the position of the hydroxyl group, confirming the number
of double bonds in the molecule and demonstrating whether
or not an epoxide group was present.
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Figure 4.5 Selected ion chromatograms of EPHETA
(Me/H2/TMS)
Following methylation, hydrogenation and TMS ether for¬
mation, the material showed two marginally resolved GC
peaks (carbon values 22.80, 22.85). Mass spectra (Figure
4.4) taken at these carbon values were very similar and
indicated the presence of three double bonds in the
original material (the methyl ester of oleic acid epoxide
was unaffected by the hydrogenation procedure so it was
assumed that if an epoxide group was present in the mole¬
cule, it would be unaffected). In these mass spectra, the
large ion fragments at m+/e 273 and 257 provided strong
evidence that the TMS group was in the C-10 position as
these ions corresponded to cleavage at either side of a
TMS group in this position. The mass spectra indicated
that very small amounts of partially hydrogenated material
may be present but this did not account for the two mar¬
ginally resolved GC peaks, as the same GC profile as the
total ion chromatographic profile was observed in the
single ion chromatograms of the ion fragments at m+/e 413,
307, 273 and 257 (Figure 4.5). This suggested that iso¬
mers of the molecule were present.
It is well known that lithium aluminium hydride (LiAlH^)
reduces an epoxide group to a mono-alcohol. Two positional
isomers are usually formed (Hamberg and Gotthammar, 1973).
During this reaction, an ester moiety would also be re¬
duced to a primary alochol. Gas chromatography of the TMS
derivative of the product of the LiAlH^ reaction showed a


















Figure 4.6 Reaction scheme for LiAlHi, reduction
consistent with the products of the reaction scheme shown
in Figure 4.6. The ratio of the relative abundance of the
ion fragments at m+/e 313/227 and m+/e 2.27/213 altered in
spectra taken at different positions on the GC peak
(Figure 4.7) which suggested the presence of two slightly
resolved components and indicated that the 1,3-product had
a slightly shorter retention time than the 1,2-product.
The GC-MS examination of the products of this reaction
provided evidence for the presence of an epoxide group in
the original material.
Gas chromatography of the n-butyl boronate/TMS derivative
of the product of the LiAlH^ reaction indicated that none
of the TMS product described above remained and showed
two partially resolved peaks (carbon values 23.8 and 24.2)
with very similar mass spectra. These were consistent with
the proposed products (Figure 4.6). The mass spectra
contained a large number of low molecular weight ion frag¬
ments and in addition, diagnostic ion fragments at m+/e 462
(molecular ion), 447, (M-CH3), 378 (M-OBBu) and 372 (M-
TMSOH). It was not possible to distinguish between the
two GC components and therefore determine whether or not
the two GC peaks corresponded to the two different pro¬
ducts. This seemed a likely explanation. Since only 1,2-
and 1,3-diols readily form boronates, the formation of the
boronate derivative indicated that the hydroxyl group was
adjacent to the epoxide in the original material and
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Figure 4.7 Mass spectra of EPHETA (Me/LiAlH^/TMS)
o 10 20 30 40
Fraction (1 min)
Figure 4.8 HPLC radiochromatogram of Zone II
High performance liquid chromatography (solvent system
HPLC 2) of Zone II of the liquid-gel chromatographic sepa¬
ration showed two partially resolved peaks (Figure 4.8)
which were shown to have identical carbon values on GC
(22.05) as their Me/TMS derivatives and very similar mass
spectra. These isomers had HPLC retention times between
those of PGB2 and 12-HETE (which were recorded on one
occasion as: PGB2 30 min) EPHETA (A) 13 min) EPHETA (B)
15 min) 12-HETE 7.5 min). It was considered that the
isomers resolved by HPLC were probably hydroxyl stereo¬
isomers or geometrical epoxide isomers.
All the evidence outlined above indicated that this zone
of the liquid-gel chromatographic separation contained
isomers of 10-hydroxy-l1,12-epoxy-5,8,14-eicosatrienoic
acid (EPHETA) and not the proposed THETA intermediate,
8-hydroxy-ll,12-epoxy-5,9,14-eicosatrienoic acid. Further
work is required to establish the configurations of the
hydroxyl and epoxy groups. It was considered probable
that the 5,6-, 8,9- and 14,15-double bonds had remained
cis.
In the gas chromatogram of the Me/TMS of a horse platelet
incubate, peak 2 (Figure 3.1) (carbon value 22.05) was
shown to contain EPHETA. EPHETA was similarly identified
in washed platelet incubates from human, dog, rabbit and
cat. However, spectra obtained from these samples were
not useful for determining the structure of EPHETA as ion
fragments from even small amounts of the "12-HETE GC de-
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composition product" were significant at the carbon value
of EPHETA and unnecessarily complicated the structure
elucidation of the then unidentifed material. In these
samples, selected ion monitoring of the ion fragments at
m+/e 269 (base peak of EPHETA, Me/TMS) and m+/e 213
(principal ion fragment from the 12-HETE GC decomposition
product Me/TMS) indicated that the single ion chromato-
grams of these ions had different GC profiles and were
therefore derived from different components. This illus¬
trated the necessity of the liauid-gel chromatographic
clean-up of the platelet extract, prior to a GC-MS inves¬
tigation of the structure of EPHETA, in order to remove
these interfering components and hence simplify the in¬
terpretation of the mass spectra obtained.
Investigations using Epoxide Standards
While the structural elucidation work on EPHETA was in
progress, a series of experiments was undertaken with the
aim of determining the stability of an epoxide moiety
under various conditions. These were necessary to esta¬
blish reaction conditions for the LiAlH^ reduction carried
out on EPHETA, and to determine any potential effects of
the standard derivatisation procedures employed. The
results of these experiments are described in the remain¬
der of this section.
An analogous model compound consisting of a straight chain
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Figure 4.11 Mass spectrum of the product of the methyl ester
of oleic acid epoxide after treatment with oxi-
mating reagents in pyridine and TMS ether formation
epoxide was desired but was not available. However, the
methyl ester of oleic acid epoxide, 10a,lla-epoxy-ll-deoxy-
PGF2 a an<3 the corresponding S-epoxy compound were avail¬
able as standards.
It is noteworthy that epoxide moieties are well documented
as being stable under gas chromatographic conditions (for
example, McDonough and George, 19 70 J Emken, 1971, I972j
Gunstone and Jacosberg, 1972). The three available stan¬
dards were initially examined for any effects due to the
methylation, silylation and hydrogenation procedures em¬
ployed.
Gas chromatography of the methyl ester of oleic acid
epoxide gave a single GC peak (carbon value 19.6) whose
mass spectrum was very similar to that previously reported
(Ryhage and Stenhagen, 1963)'. Treatment with BSTFA was
shown to have no effect on the compound. GC-fS examina¬
tion of the Me/TMS derivatives of the two prostaglandin
analogues resulted in a single GC peak for each compound
(carbon value a 24.0) f3 24 . 3). Their mass spectra (Figure
4.9 and Figure 4.10 respectively) were interesting to
compare as the relative abundance of the ion fragments in
the different epoxide isomers varied considerably. The
epoxide grouping in these compounds was clearly unaffected
by the methylation and silylation procedures employed.
It was also demonstrated that the methyl ester of oleic
acid epoxide was unaffected by the hydrogenation pro¬
cedure .
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Potential effects of the oximating procedure were then in¬
vestigated. When the methyl ester of oleic acid epoxide
was subjected to the oximating procedure of reaction
with methoxy- or butoxy-amine hydrochloride in pyridine,
followed by TMS ether formation of the product (using
BSTFA with or without 1% trimethylchlorosilane), the major
GC peak did not correspond to the original epoxide and
had a longer GC retention time (carbon value 21.6). This
same major product was present whether methoxy- or butoxy-
amine hydrochloride was used so it was concluded that the
product did not contain the alkoxy group of the oximating
reagent. The mass spectrum of this product (Figure 4.11)
showed similarities with that obtained from 9,10-(bis TMS)
-methyl stearate (carbon value 21.5) as both spectra con¬
tained their largest ion fragments at m+/e 259 and 215.
The carbon value of the "product of the oximation pro¬
cedure" was 0.1 of a carbon value higher than that of meVh^L
spectra showed certain significant differences. A close
examination of the mass spectrum of the unidentified pro¬
duct indicated the presence of the chlorine isotope
pattern (35C1 75%, 37C1 25%) in various ion fragments and
was concluded that the mass spectrum solved for a mixture
of the two chloro-TMS compounds shown in Figure 4.11.
The reaction of an epoxide group with trimethylchloro¬
silane in pyridine was reported by Harvey et al (Harvey,
Johnson and Horning, 1972; Harvey, Glazener, Stratton,
and a comparison of the mass
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Johnson, Hill, Horning and Horning, 1972) to produce a
TMS derivative of the chlorohydrin adduct. This reaction
procedure was applied to the methyl ester of oleic acid
epoxide (it is noteworthy that during this reaction, a
copious white precipitate formed, presumably pyridine
hydrochloride). Any additional hydroxyl groups in the
molecule were then silylated by the addition of BSTFA to
the reaction mixture (which also dissolved the white
precipitate). GC-MS examination of this product indicated
that the major GC peak had an identical carbon value and
mass spectrum as the derivatised product resulting from
the oximation reaction and thus confirmed the structure
of the derivatised products of the oximation reaction as
the two chloro-TMS compounds shown in Figure 4.11.
Oximation can also occur under acidic aqueous conditions
(Jones, 1972). In the case of the methyl ester of oleic
acid epoxide, this aqueous method of oximation resulted
principally in the unchanged epoxide. Only relatively
small amounts of the chloro-TMS compounds and in addition,
small amounts of onetVi^l stearate were de¬
tected. Considerably smaller amounts of the epoxide were
destroyed under these conditions and this procedure was
considered more satisfactory than that using pyridine as
solvent. The methyl ester of thromboxane B2 was deriva¬
tised as a control and was"found to oximate satisfactorily
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Figure 4.12 Mass spectra of products of a-epoxide
The effects of the pyridine oximating conditions on both
the a- and g-epoxide prostaglandin analogues were then in¬
vestigated. In contrast to the oleic epoxide standard,
GC-MS examination of the products of both compounds after
methylation, oximation and TMS ether formation indicated
that the mass spectrum of the major GC peak for each
product corresponded to that obtained previously for the
Me/TMS derivative. In addition, two very small peaks
(carbon values 25.0 and 25.7) were present in the chrom-
atogram of the a-epoxide sample and a single small broad
peak (carbon value 25.1-2) in the chromatogram of the 8-
epoxide sample. Larger amounts of these compounds were
derivatised according to the same procedure in order to
obtain spectra of these minor chromatographic peaks. The
mass spectra of these minor components were found to be
consistent with chloro-TMS products', the chlorine isotope
pattern being present in several of the high mass ion
fragments.
The two epoxides were also treated with trimethylchloro-
silane/pyridine and BSTFA as described previously. The
same products as the minor products of the oximation re¬
action were formed but in this case, they were the major
chromatographic components and smaller amounts of the Me/
TMS derivatives were present:
In the case of the a-epoxide, the mass spectra of the two
GC peaks (carbon values 25.0 and 25.7) were similar
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Figure 4.13 Mass spectra of products of 0-epoxide
Figure 4.14 Proposed reaction products from a- and f3-epoxide
analogues
different ion fragirents differed. The peak shape of the
product of the 8-epoxide suggested two partially resolved
components (carbon values 25.1 and 25.2)* the mass spec¬
tra of which (Figure 4.13) were very similar, again dif¬
fering only in the relative intensity of the different
ion fragments. The most likely explanation of these ob¬
servations is that the two products formed from these
reactions (Figure 4.14) completely resolved in the case
of the a-epoxide but only partially resolved in the case
of the 8-epoxide. It is noteworthy that in the mass
spectra the chlorine isotope effect is affected by an
isotope effect from the other atoms in the ion fragments.
These experiments indicated that the ease of opening of
the epoxide ring in oleic epoxide and the prostaglandin
analogues differed considerably and demonstrated that the
ease of opening of an epoxide moiety depended on its
chemical environment. The need for caution in applying
standard derivatisation procedures to certain epoxides
was apparent.
In the case of EPHETA, the molecule was found to be un¬
affected by the pyridine oximation procedure, although if
comparable amounts of the chloro-TMS products had been
present as those formed in the case of the a- and 8-epoxy
prostaglandin analogues, these would not have been de¬
tected. GC-MS examination of the product after treatment
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Figure 4.15 Fragmentation of EPHETA (Me/trimethylchlorc-
silane, pyridine/BSTFA)
indicated that some of the Me/TMS derivative (carbon value
2 2 .05) v/as present but it was not the major component. The
major chromatographic component was composed of a princi¬
pal peak (carbon value 24.1) which was partially resolved
from a considerably smaller peak (carbon value 24.4).
The mass spectrum of the principal peak (carbon value 24.1)
had a base peak at m+/e 269 (compare the mass spectrum of
the Me/TMS derivative, Figure 4.3) and although the most
intense ions in the spectrum corresponded to non-chlorine
TMS fragments, the distinctive chlorine isotope pattern
was present in very small ion fragments at m+/e 532, 530
(molecular ion), 517, 515 (M-CH3) and in more intense ion
fragments at 263, 261 (M-269) (Figure 4.15). The spectra
obtained from this derivative were not as definitive as
hoped, but provided additional evidence for the presence
of an epoxide group in EPHETA.
Although clearly not the ideal compound, the methyl ester
of oleic acid epoxide was used as a standard to determine
the experimental conditions for the LiAlH^ reduction and
to ascertain whether or not this reaction v/ould be feasi¬
ble on the small amounts of EPHETA which were available
(in the order of 250 p.g) . Initial experiments involved
heating the reaction mixture for 18 h and 72 h at 60°C.
GC-MS examination of the TMS derivatives of the products
indicated that while starting material was present in the
18 h sample, none remained in the 72 h sample. Two par¬







Figure 4.16 Gas chromatogram of the TMS ether of the product
of the methyl ester of oleic acid epoxide






Possible products of LiAlH^ reduction
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Figure 4.18b Mass spectrum of Peak 2, Figure 4.16
present in the 72 h sample (carbon value 20.0 and 20.3),
the longer retained peak corresponding to the minor pro¬
duct. The possible products are shown in Figure 4.17.
The mass spectra of the two GC peaks (Figure 4.18) indi¬
cated that the major peak (peak 1, Figure 4.16) corres¬
ponded to compound B (Figure 4.17) and that compounds C
and D (Figure 4.17), the required products, were present
in the minor peak (peak 2, Figure 4.16). An intense ion
fragment corresponding to the loss of a methyl group from
the molecular ion was reported to be characteristic for
TMS derivatives of alcohols (Budzikiewicz, Djerassi and
Williams, 1967a) (Figure 4.18a).
This reaction was repeated, on two subsecruent occasions,
with heating for 72 h at 60°C using a fresh supply of
LiAlH^. On each occasion, GC-MS examination of the TMS
derivatives of the products indicated that the reactions
had gone to completion, as only a single chromatographic
peak was detected whose carbon value (20.3) and mass
spectrum corresponded to the minor product detected pre¬
viously. The mass spectrum, was consistent with a mixture
of compounds C and D, the products expected from this
LiAlH^ reduction. These products would not be expected
to resolve on the GC. This same experimental procedure
was applied to provide evidence for the presence of an
epoxide group in EPHETA as described earlier.
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4 . 3 EXAMINATION OF OTHER LIQUID-GEL
CHOMATOGRAPHIC ZONES
Zone III of the Liquid-Gel Chromatographic Separation
GC-MS examination of the Me/TMS derivative of Zone III of
the liquid-gel chromatographic separation of the platelet
incubate (Figure 3.6) indicated a single major GC peak
(carbon value 19.3). The mass spectrum was consistent
with a C17 fatty acid methyl ester containing three double
bonds and one TMS group and was in agreement with that
reported for the Me/TMS derivative of the C17 hydroxy
acid HHT (Hamberg and Samuelsson, 1974a).
A comparison of the amounts of HHT present as indicated
by scintillation counting and GC-MS did not correlate
satisfactorily and indicated that possibly another com¬
ponent was present in this zone from the liquid-gel
chromatographic separation. The formation of HHT is
inhibited by indomethacin as it is a product of the
prostaglandin cyclo-oxygenase pathway. A radioactive
peak was still present in this zone of the liquid-gel
chromatogram when indomethacin was present in the platelet
incubate. GC-MS examination of the Me/TMS derivative of
this incubate confirmed that the HHT biosynthesis had
been virtually completely inhibited, as only trace
amounts of HHT were detected. There were not, however,
any other significant chromatographic peaks except that
105
attributable to the indomethacin derivative which was
found to chromatograph in this zone of the liquid-gel
column. The indomethacin derivative (methyl ester) posses¬
sed a higher carbon value (25.6) than previously detected
arachidonic acid metabolites and therefore the potential
gas chromatographic interference of the indomethacin
derivative was discounted.
After methylation followed by oximation (using methoxy-
and butoxy-amine hydrochloride) and TMS ether formation
or treatment of the material with trimethylchlorosilane/
pyridine and BSTFA (in attempts to detect a chromato-
graphically unstable epoxide) of samples of zone III
(both from incubates with and without indomethacin pre¬
sent) , no additional product was detected by GC-MS. This
indicated that this product had not been stabilised for
gas chromatography by the derivatisation procedures em¬
ployed. In addition, GC-MS examination of the Me/TMS
derivative of Zone III after further incubation with
washed human platelets did not result in the detection of
any additional compound. This indicated that this zone
did not contain a compound which was an intermediate in
the formation of any of the previously mentioned com¬
pounds. Further work is required to identify this pro¬
duct (s) of the platelet incubation which is not formed
via the prostaglandin cyclo-oxygenase pathway.
In order to check that this additional product was not
an auto-oxidation product of arachidonic acid, arachidonic
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Figure 4.19 Mass spectrum of unidentified material (Me/TMS)
acid (containing 1- 1 Zl-arachidonic acid as tracer) was
heated at 37°C for 30 min in Krebs-Henseleit buffer and
extracted in the same manner as the platelet incubates.
The extract was then subjected to liquid-gel chromato¬
graphy. The resultant chromatogram indicated that there
was no radioactivity in this zone from the chromatographic
separation and demonstrated that the unidentified material
was a product formed as a result of the presence of
platelets in the incubations.
Zone VI of the Liquid-Gel Chromatographic Separation
On one occasion, very small amounts of radioactivity were
detected in fractions of the liquid-gel chromatographic
separation (Zone VI, Figure 3.6) which eluted later than
those containing 8 ,11,12-THETA and thromboxane B2 . GC-MS
examination of the Me/TMS derivative of these fractions
showed a single GC peak (carbon value 24.3) whose mass
spectrum (Figure 4.19) indicated a compound of molecular
weight m+/e 600. Comparison of the spectra of the Me/TMS
and Et/TMS derivatives demonstrated which ions in the Me/
TMS spectrum contained the ester group and indicated that
the base peak in the Me/TMS spectrum, at m+/e 301 and the
large ion fragment at in+/e 275 did not contain the ester
moiety, whereas the large ion fragments at m+/e 387 (M-
213) and m+/e 259 did. Difficulty was encountered in
attempting to rationalise the large ion fragments at m+/e
301 and 387 as resulting from the same molecule. The
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spectra contained certain characteristic "prostaglandin-
like" ions. For example, the ions at m+/e 173 which would
normally indicate a TMS group in the C-15 positionj m+/e
199 which would be attributable to the w side chain", m+/e
217 which was indicative of a 1,3 di-TMS functionm+/e
191 the base peak of PGF2a (Me/TMS) which is this pros¬
taglandin derivative is attributable to the ion fragment
(CgHg OTMS). The material did not form an oxime which
indicated that no keto group or hemi-acetal moiety was
present in the molecule. The mass spectra of this
compound(s) were not solved since further material did
not become available and therefore further structural
elucidation was not possible.
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4.4 CONCLUDING REMARKS
Investigation by GC-MS of the radioactive zones of the
liquid-gel chromatographic separation, other than those
described in Section 3, resulted in the detection of a
compound analogous to the proposed THETA intermediate (8-
hydroxy-11,l2-epoxy-5,9,14-eicosatrienoic acid). The
formation of this analogous compound, like THETA, was not
inhibited by indomethacin but was inhibited by ETYA.
Examination of a number of derivatives indicated its
structure as 10-hydroxy-l1,l2-epoxy-5,8,14-eicosatrienoic
acid (EPHETA) and not the proposed THETA intermediate.
Isomers of EPHETA were resolved by high performance liquid
chromatography.
A possible mechanism suggested for the formation of
EPHETA involved further transformation of 12-HPETE)
analogous conversions of CI8 fatty acid hydroperoxides
have been reported (Gardner, Kleiman and Weisleder, 1974 ",
Hamberg, 1975).
Non-allylic epoxy-hydroxy acids are considerably more
stable towards nucleophiles than allylic epoxy-hydroxy
acids. ll-Hydroxy-12,13-epoxy-9-octadecenoic acid (a non-
allylic epoxy-hydroxy acid) is stable in aqueous ethanol
at 100°C for at least 3 hours (Hamberg and Gotthammar,
1973) whereas under the same conditions, 9-hydroxy-12,13-











is converted into a mixture of 9 ,10,13-trihydroxy-ll-
octadecenoic acid and 9,12,13-trihydroxy-10-octadecenoic
acid (Hamberg, personal communication). It would there¬
fore seem probable that both 10-hydroxy-11,12-epoxy-5,8,14-
eicosatrienoic acid (EPHETA) and the proposed THETA inter¬
mediate, 8-hydroxy-ll,12-epoxy-5,9,14-eicosatrienoic acid
form from 12-HPETE (compare Hamberg, 1975). Only the
former more stable non-allylic epoxy-hydroxy acid
accumulated and was detected whereas the latter, less
stable allylic epoxy-hydroxy compound was converted to
THETA by the addition of water (Figure 4.20) and was
therefore not detected. It is noteworthy that solutions
of EPHETA stored at -20°C in methanol were stable for
several months. Attempts to detect the proposed THETA
intermediate by shortening the incubation period were
not successful.
The product of the platelet incubate which co-chronato-
graphed with the C17 monohydroxy acid HHT has not been
identified and further work is renuired to determine the
structure of this material. Maclouf et al (Maclouf,
Bernard, Rigaud, Rocquet and Breton, 1977) detected a
similar product on incubating arachidonic acid with spleen
microsomes from whole body irradiated rats. The formation
of their product, which co-chromatographed on TLC with HHT,
was similarly not inhibited by indomethacin. They did not
identify their product.
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It was of interest whether or not these compounds possessed
any pharmacological activity and a number of tests were
performed which are described in Section 5 of this thesis.
Ill
SECTION 5
THE PHARMACOLOGICAL TESTING OF THE NEV7LY
IDENTIFIED ARACHIDONIC ACID METABOLITES
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5.1 INTRODUCTION
The newly identified arachidonic acid metabolites were
tested in "prostaglandin-sensitive" biological assay
systems in order to determine whether or not they possessed
similar biological activity to the prostaglandins. These
tests included their effects on platelet aggregation
(either pro-aggregatory or anti-aggregatory with respect
to aggregation induced by arachidonic acid and ADP), cat
blood pressure and their ability to contract strips of
rabbit aorta, rat fundus and guinea pig ileum..
In addition, the effects of these compounds on enzymes
involved in prostaglandin synthesis (prostaglandin cyclo-
oxygenase, thromboxane synthetase and PGI2 synthetase)
were determined. The effects on the first two enzymes
were determined from the platelet aggregation studies and
the effect on PGI2 synthetase from experiments involving
incubation of arachidonic acid with aortic rings.
The chemotactic activity of each of the compounds was also
determined in particular because the lipoxygenase product
12-HETE had been reported to possess this type of activity.
In addition, there were reports (at times conflicting)
concerning the activity of several prostaglandins, throm¬
boxane B2 and HHT. These reports are fully referenced
later in this section.
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Quantification of the arachidonic acid metabolites tested
in these studies were determined on small amounts of each
sample, both by liquid scintillation counting and by com¬
parison of the peak area of the Me/TMS derivative on GC-MS
with standard C22 and C24 fatty acid methyl esters. Good
correlation (less than 20% variation) was obtained for
8,11,12-THETA (samples containing less than 10% throm¬
boxane B2, which was accounted for in the quantification,
were chosen for testing), 8,9,12-THETA and EPHETA. Zone
III was quantified only by scintillation counting - an
estimation of the amounts of HHT present by GC-MS indi¬
cated that only 25-40% of the radioactivity in Zone III
was accounted for by the HHT. It was considered that any
pronounced biological activity of the additional un¬
identified material (section 4.3) would be detected, as
HHT itself has not been reported to have activity other
than being chemotactic at high doses (Goetzl and Gorman,
1978) .
The chemotaxis work described in this section was per¬
formed with Dr. P. J. Kerry. The experiments on the cats
were carried out with Dr. R. L. Jones.
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5.2 RESULTS OF PHARMACOLOGICAL TESTING
1. Platelet Aggregation
In the case of prostaglandins, the platelet aggre¬
gation assay system is sensitive to the anti¬
aggregatory substances PGI2 , PGD2 and PGEj. The
reader is referred to a paper by Moncada et al
(Moncada, Vane and Whittle, 1977) for a comparison
of the relative potency of these inhibitors of
platelet aggregation in several species. The assay
is also sensitive to the prostaglandin endoperoxides
(Hamberg, Svensson, Wakabayshi and Samuelsson, 1974)
and the highly unstable thromboxane A2 (Hamberg,
Svensson and Samuelsson, 1975) which induce irrever¬
sible aggregation.
8,11,12-THETA, EPHETA and Zone III from the liquid-
gel chromatographic separation (at a concentration of
10 pg.ml *) had neither pro-aggregatory effects nor
anti-aggregatory effects (with respect to aggregation
induced with arachidonic acid or ADP). However, a
partial inhibitory effect of the 8,9,12-THETA
solution (10 jig.ml to aggregation induced with
either arachidonic acid or ADP was detected. The
response was equivalent to that caused by 12.5 ng of
PGD2, a possible contaminant.
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PGD2 is unstable under basic conditions and a sample
of the 8,9,12-THETA solution was treated with base to
determine the likelihood of contamination. Basic
conditions (which were demonstrated to abolish the
effects of a PGD2 standard on platelet aggregation)
resulted in the loss of anti-aggregatory activity of
the 8,9,12-THETA solution without loss of 8,9,12-
THETA as indicated by GC-MS analysis. The presence
of PGD2 was not, however, confirmed by GC-MS.
Attempts, which involved preparing the remainder of
the sample (approximately 10 pg 8,9,12-THETA) as the
Me/BuO/TMS derivative and selected ion monitoring,
indicated that the derivatised sample was not
sufficiently clean to satisfactorily determine
whether or not the very small amounts of PGD2 indi¬
cated by the platelet experiments were present. PGD2
would be expected to elute from the liquid-gel
column with a similar retention to 8,9,12-THETA and
it was deduced that the anti-aggregatory activity
observed in the 8,9,12-THETA solution was almost
certainly attributable to the presence of small
amounts of PGD2 .
It was concluded that none of the compounds had any
significant effect on the platelet aggregation
response.
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2. Prostaglandin I2 Production
It was of interest to determine if any of the com¬
pounds affected the prostaglandin cyclo-oxygenase,
thromboxane synthetase or PGI2 synthetase enzymes.
If any of the compounds had an inhibitory effect on
either the prostaglandin cyclo-oxygenase or throm¬
boxane synthetase, this would have resulted in an
effect on the platelet aggregation response to
arachidonic acid (Section 5.2.1). It was therefore
concluded that none of the novel arachidonic acid
metabolites had an effect on these enzymes at the
concentrations tested.
In order to determine their effect on PGI2 bio¬
synthesis, a biological assay method, as opposed to
a GC-MS assay method, was developed as it was con¬
sidered that the biological assay was simpler to
develop and use, and would provide a faster indi¬
cation of any inhibitory effect of the compounds. It
was intended to develop a more precise GC-MS assay
should the biological assay indicate that any of the
metabolites possessed inhibitory action.
The biological assay method involved incubation of
aortic rings with arachidonic acid to produce PGI2 ,
transfer of a portion of the incubate to a platelet
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Figure 5.1 Platelet aggregation assay system for PGI2
gation response induced by ADP. PGI2 is the most
potent anti-aggregatory naturally occurring prosta¬
glandin. It is considerably more potent than PGD2
or PGEj (Moncada, Vane and Whittle, 1977).
It was initially determined that transfer of 0.05 ml
of the aortic ring incubate to the platelets,
followed by addition of ADP, resulted in a slight
inhibitory response whereas transfer of 0.1 ml
completely abolished the ADP response. In all sub¬
sequent determinations, 0.1 ml of the incubate was
transferred - this dose was considered suitable as
it would completely inhibit the ADP response but was
not a higher dose than was necessary to cause this
effect.
Any compound which inhibited either the prostaglandin
cyclo-oxygenase or PGI2 synthetase enzymes should
result in an aggregation response on the addition of
ADP. This was ascertained using the prostaglandin
cyclo-oxygenase inhibitor indomethacin (20 pM)
(Figure 5.1). After pre-incubation of the aortic
rings with either 8,11,12-THETA, 8,9,12-THETA or
EPHETA (at a concentation of 10 p.g.ml * in the aortic
incubate), incubation with arachidonic acid and
transfer of 0.1 ml of the incubate to the platelet
aggregometer, the ADP response was completely






Figure 5.2 Responses of PGE2 , 8,11,12-THETA and 8,9,12-THETA
on the rat fundus
base as described in Section 5.2.1 before testing).
This indicated that, at this concentration, these
compounds had no inhibitory effect on either the
prostaglandin cyclo-oxygenase or PGI2 synthetase
enzymes.
Tissue Preparations
The tissue preparations examined were the rabbit
aorta which contracts in response to thromboxane A2
and the prostaglandin endoperoxides (Needleman et al
1976) and the rat fundus and guinea pig ileum which
contract in response to the classical prostaglandins
PGE2 and PGF2a (Horton and Main, 1965 ) Gilmore, Vane
and Wyllie, 1968). The sensitivity of the rabbit
aorta was ascertained using a 50 ng dose of 11,9-
epoxymethano-PGH2 (a thromboxane A2 mimic) and the
sensitivity of the other two tissues was ascertained
using PGE2 (10-40 ng) and PGF2a (20-40 ng).
At a dose of 1 pg EPHETA and 2 pg Zone III, there
were no effects observed on any of the assay tissues
On the rabbit aorta, doses of 1 and 2 pg 8,11,12-
THETA and 8,9,12-THETA did not produce any response.
The 8,11,12-THETA solution, at doses of 1 and 2 pg
8,11,12-THETA, produced minimal contractions on the
rat fundus (less than the response of 20 ng PGE2 or










Figure 5.3 Responses of 8,9,i2_THETAf
guinea pig ileum
pGE2 and 8,11,12 -THETA on the
present in the 8,11,12-THETA solution did not account
for these contractions (Boot, Dawson, Cockerill,
Mallen and Osborne, 1977). On the rat fundus, the
8,9,12-THETA solution at a dose of 1 pg 8,9,12-THETA
produced a minimal response. Doubling the dose pro¬
duced a response equivalent to 20 ng PGE2 (Figure 5.2).
On the guinea pig ileum, doses equivalent to 1 and
2 pg 8,11,12-THETA produced minimal contractions
(less than the response of 10 ng PGE2 , 40 ng PGF2Ct)
and 2 pg 8,9,12-THETA caused a similar contraction to
10 ng PGE2 (Figure 5.3).
It was initially considered possible that the 8,9,12-
THETA solution was contaminated v/ith small amounts
of PGE2. However, treatment of the solution under
basic conditions (which destroyed the activity of a
PGE2 standard) did not result in any loss of activity.
GC-MS examination of the Me/BuO/TMS derivative of a
sample (25 pg 8,9,12-THETA) of the solution by
selected ion monitoring confirmed the absence of
PGE2 in the sample.
In summary, none of the newly identified arachidonic
acid metabolites tested had potent contractile





Chemotaxis can be defined as a reaction by which the
direction of locomotion of cells is determined by
substances in their environment. In contrast, chemo-
kinesis can be defined as a reaction by which the
speed or frequency of locomotion and/or the frequency
and magnitude of turns of cells is determined by
substances in their environment. Chemokinetic
responses can arise from the increase in velocity of
cells moving at random, whereas chemotactic responses
are caused by a concentration gradient (Wilkinson and
Allan, 1978). In inflamed tissues, it is stated that
chemotactic substances attract leukocytes from
vessels to the site of inflammation.
Perhaps the most common method for measuring chemo¬
taxis in vitro is that devised by Boyden (1962) .
Although the Boyden chamber has undergone modifi¬
cation from the original design, the principle re¬
mains the same. The basic concept of assaying
chemotaxis by this method is very simple and in¬
volves incubating the cells in the presence of
different stimuli and determining and comparing the
migration of cells in different samples.
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Two principal counting methods for determining chemo-
tactic effects are used. The first method involves
counting the number of cells that have reached the
lower surface of the filter after a given time
period. The second, referred to as the leading front
technique (Zigmond, 1974) involves incubating the
cells for a shorter period of time, which allows the
cells to migrate into the filter but not to traverse
its complete depth. A measure is made of the dis¬
tance migrated by the leading front two cells. The
first technique was used in this study as it was
considered it would be the simpler to establish.
Rabbit peritoneal PMNL were used as these cells were
the most readily obtained. The chemotaxis assay
system clearly required a positive control to check
that the cells would respond satisfactorily and
initially, it was decided to use PGEi for this pur¬
pose as Kaley and Weiner (1971)) Higgs, McCall and
Youlten (1975)^ Walker, Smith and Ford-Hutchison
(1976) had all reported that PGEj was chemotactic
for these cells.
The Search for a Positive Control
In this study, numerous experiments using PGEi at
concentrations of 1 and 10 (ig.ml ^ indicated that
this substance was exerting neither a chemotactic
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nor chemokinetic influence and was therefore not
useful as a positive chemotactic agent. Reports by
a group of Japanese workers (Shibuva, Masuda and
Izawa, 1976) and Diaz-Perez et al (Diaz-Perez,
Goldyne and Winkelmann, 1976) indicated that they
had also been unable to demonstrate that PGEi was
chemotactic for rabbit PMNL.
A similar controversy existed on the chemotactic
effect of PGF2 a (Higgs et al, 1975", Shibuya et al,
1976", Diaz-Perez et al, 1976) for rabbit PMNL. In
this study, experiments using PGF2 a at doses of 1 and
10 (ig.ml ^ indicated that there was no chemotactic
response for the rabbit cells.
Due to the failure of PGEi and PGF2 a to elicit' a
response, a positive chemotactic agent was still
required to check that the cells would respond
satisfactorily. Shibuya et al (1976) used casein as
their positive control and determined that the
optimum dose was 0.2% (w/v) casein. Although this
concentration was very high and the substance was
not related structurally to the compounds to be
tested, the optimum dose of casein by the Japanese
workers was found to induce both a chemokinetic and
chemotactic response in this study. Casein was
therefore used as a positive control in all subse¬
quent experiments. It is noteworthy that the chemo-
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Note: the values shown are the mean (+ standard deviation) from
three separate experiments
Figure 5.4 Equilibration of PGF2Q in the Boyden chamber
tactic constituents of crude casein have not been
identified although it has been observed that the
activity was easily extracted into organic solvents.
An examination of the extract by gas chromatography
indicated that several free fatty acids were present
(Turner and Lynn, 1978) , one or a number of which may
be responsible for the chemotactic activity. The
responses of PGEi and PGF2a were determined on
several occasions using casein as a positive control
and confirmed the above observations concerning their
lack of activity. Despite many reservations about
this use of casein, on two occasions during the
subsequent studies, casein produced only a very
slight response and indicated that the cells were
not responding in the normal manner.
A negative control in which chambers containing only
fortified TC199 were prepared, was demonstrated to
be necessary as cell counts from this sample varied
considerably. Occasionally, the cell counts were
very high and the results from these experiments
were therefore meaningless. Normally, the back¬
ground count was only one or two cells per high
power field.
Equilibration Studies
A disturbing report (Shibuya et al, 1976) suggested
that the concentration gradient of PGF2a (as
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Control chamber
EPHETA 5 ng.ml 1
Test Chamber
EPHETA 5 fig.ml"1
Figure 5.5 Photographs of microscope slide preparations







































Results show the mean number of cells in 5 high-
power fields (objective x40) + the standard error
When duplicate values are shown, these were ob¬
tained from two separate chambers
* Too many cells to count accurately
measured by RIA) in the Boyden chamber was not main¬
tained over the 3 hour incubation period. As the
concentration gradient is crucial to the concept of
chemotaxis, these experiments were repeated in this
study using PGF2 a (1 pg.ml "*") containing 3H-PGF2a as
tracer. Scintillation counting of samples from both
compartments of the chamber after different incu¬
bation times indicated that less than 20% of the
PGF2a had migrated after 3 hours (Figure 5.4) and
that a significant concentration gradient was main¬
tained during the course of the experiments.
The Effect of the Newly Identified Arachidonic Acid
Metabolites
Neither 8,11,12-THETA nor 8,9,12-THETA, at a concen¬
tration of 1 pg.ml ^ showed any increase in cell
count over blank values in either the control or
test chambers. The EPHETA solution however produced
a dramatic visible response at concentrations of 1
and 5 pg.ml ^ EPHETA (Figure 5.5). When the cells
were counted, control values were seen to be very
similar to the blank values (Table 5.1) and it was
immediately apparent that a significant chemotactic
influence was being exerted. Further purification of
the zone of the licruid-gel chromatographic separation
containing EPHETA (Zone II, Figure 3.6) was achieved
by HPLC. Two isomers of EPHETA were resolved during
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this chromatographic purification (Section 4.2).
Chemotactic testing of the fractions containing each
of two isomers indicated that virtually all activity
was attributable to the fractions containing the more
polar HPLC isomer. The HPLC purification procedure
had removed any traces of 12-HETE from the two
epoxide isomers. This was significant as reports
(Turner et al, 1975) Turner and Lynn, 1978) Goetzl,
Woods and Gorman, 1977) Goetzl and Gorman, 1978)
indicated that 12-HETE was chemotactic for human peri¬
pheral blood PMNL. The presence of activity in the
HPLC purified material provided very strong evidence
that the observed activity was indeed due to EPHETA.
It was possible that the 12-HETE prepared by Turner
et al (from incubating washed platelets with arachi-
donic acid) may have contained EPHETA as only one
TLC purification was employed. Therefore, their
purification method was repeated in this study and
indicated that their 12-HETE should have been satis¬
factorily resolved from any EPHETA that might have
been present in their original extract.
Concluding Remarks
It is considered worth emphasising that the Boyden
chamber can only satisfactorily be used with all the
controls that are employed in this study. Several
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workers are guilty of not employing all these con¬
trols, which has resulted in confusion in the inter¬
pretation of data. Care must be taken in preparing
fresh solutions of compounds for testing as, for
example, "aged PGEi solutions" have been reported to
show increased chemotactic activity (Walker et al,
1976). Lack of these precautions may in part
explain some of the conflicting results.
In view of the many conflicting results obtained
using the Boyden chamber (in addition to those pre¬
viously mentioned) , the reader is referred to
Kitchen, Boot and Dawson, 19 78", Goetzl and Gorman,
1978 concerning thromboxane B2), it is intended
that further work will be carried out on EPHETA to
substantiate the effects observed in the Boyden
chamber by another method. Chemotactic activity was
reported to be accompanied by a concommitant release
of the enzymes 6_galactosidase and g-glucuronidase
(Wilkinson, 1974) and it is hoped to monitor the
release of these enzymes during the incubation
process.
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5. Blood Pressure Experiments
It was of interest to determine whether or not either
of the trihydroxy acids or EPHETA had any effect on
blood pressure. This interest was stimulated by
reports by Wennmalm (1977) and Bayer and FUrster
(1979) that the vasodepressor effect they obtained
from arachidonic acid could not be completely aboli¬
shed by pre-treatment with indomethacin. It was
suggested that an arachidonic acid metabolite which
was not a product of the prostaglandin cyclo-
oxygenase pathway might be responsible for these
effects .
Blood pressure experiments were carried out on two
male cats. The sensitivities of the preparations
were checked using PGE2 (1 fig) which caused a fall
in blood pressure. Infusion of arachidonic acid
(300 pg.kg *) resulted in an increase in blood
pressure. In contrast to the previously mentioned
reports, after infusion of indomethacin (1 mg.kg *),
the effect of arachidonic acid was completely aboli¬
shed. After further treatment with indomethacin
(0.5 mg.kg 1), the dose of arachidonic acid was
doubled but the response was still completely
blocked by the indomethacin. The increase in blood
pressure following arachidonic acid infusion was












Figure 5.6 The effects of PGF2ct, PGE2 and 8,9,12-THETA on cat blood
pressure
butable to the formation of this prostaglandin,
PGD2 , the prostaglandin endoperoxides or throm¬
boxane Aa. It is noteworthy that 11,9-epoxymethano-
PGH2 (a thromboxane A2 mimic) causes an increase in
blood pressure in the cat (R. L. Jones, unpublished
results).
Infusion of 25 pg of 8,11,12-THETA and EPHETA pro¬
duced no effect. The 8,9,12-THETA solution, at a
dose of 25 pg 8,9,12-THETA, caused a slight decrease
in blood pressure (Figure 5.6). This response was
slightly less than the effect caused by 0.5 pg PGE2 .
As described in Section 5.2.3., an examination of
the 8,9,12-THETA solution by GC-MS indicated that
this solution was not contaminated with any signi¬
ficant amounts of PGE2 and therefore it was concluded
that 8,9,12-THETA probably possessed very slight
vasodepressor properties. Further purification and
re-testing would be necessary for confirmation of
this slight activity.
Blood was collected from one of the cats and PRP
and washed platelets were prepared as described
previously (Section 2.2) and incubated with ara-
chidonic acid. GC-MS examination of the Me/TMS
derivative of the products indicated that the plate¬
lets formed 12-HETE, EPHETA and THETA. No throm¬
boxane B2 or HHT were detected which indicated the
effectiveness of the indomethacin treatment.
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5.3 CONCLUDING REMARKS
The fairly wide range of biological tests applied to the
newly discovered arachidonic acid metabolites resulted
only in a pronounced response by EPHETA in the chemotaxis
assay.
The small contractile response of the strips of guinea
pig ileum and rat fundus to the trihydroxy acid solutions
are comparable to the effects of 'two analogous CI 8 tri¬
hydroxy acids reported by a Russian group of workers
(Panosyan, Avetisyan, Mnatzakanyan, Asatryan, Vartanyan,
Boroyan and Batrakov, 1979). They isolated their material
(a mixture of 9,12,13-trihydroxy-l0,15-octadecadienoic
acid and 12,15,16-trihydroxy-9,13-octadecadienoic acid)
from the roots of a wild plant of the marrow family
(Bryonia Alba L). This plant had been used from ancient
times in folk medicine and homoeopathy and these workers
were attempting to determine the active principles.
A difficult problem in this area of pharmacological re¬
search is to decide which biological tests to apply.
There is always the possibility that one or more of these
compounds may possess activity in a biological system
which was not investigated in this study. An obvious
limitation is the amount of material necessary for
thorough biological screening. The large scale incu¬
bations employed in this study were only adequate for the
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preparation of microgram quantities of the novel metabo¬
lites. It is an additional problem, when biological
activity is detected in samples from biological extracts,
to prove that the activity is indeed due to the metabo¬
lites under test. When biological activity is detected,
it is necessary to determine the effect(s) on the observed
activity of further chromatographic purification(s) of the
sample.
There is also the possibility, in analogy with the pro¬
ducts resulting from the prostaglandin cyclo-oxygenase
pathway, that an intermediate compound (such as the THETA
intermediate) may possess considerably more biological
activity than the stable end products. This type of


















Two trihydroxy acids (8,11,12-THETA and 8,9,12-THETA) and
an epoxy-hydroxy acid (EPHETA) have been detected and
identified as novel metabolites of arachidonic acid from
incubations with washed blood platelets from human, horse,
dog, cat and rabbit. It was demonstrated that these pro¬
ducts did not arise from the prostaglandin cyclo-oxygenase
pathway as their formation was not inhibited by indo-
methacin and the most likely method of formation involved
further transformation of 12-HPETE.
The known transformations of arachidonic acid by blood
platelets are summarised in Figure 6.1. Enzymes have been
characterised for the conversion of arachidonic acid to
the prostaglandin endoperoxides, conversion of the endo-
peroxides to thromboxane A2 and HHT, and conversion of
arachidonic acid to 12-HPETE (Hammarstrfim and Falardeau,
1977j Nugteren, 1975). The transformation of 12-HPETE to
12-HETE was considered by Nugteren to be both enzymic and
non-enzymic. Further work requires to be carried out to
determine whether or not the other products are formed
enzymatically.
It is of interest to note that Falardeau et al (1976)
tentatively identified the corresponding trihydroxydienoic
acids (THEDA) to THETA from incubations of dihomo-y-
linolenic acid with washed human platelets but did not
establish a similar conversion from arachidonic acid.
They also identified two dihydroxy-trienoic acids as pro¬
ducts but did not detect a compound analogous to EPHETA.
¥
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The analogous dihydroxy acids derived from arachidonic
acid have not been detected in this study. While dihomo-
y-linolenic acid is a good substrate for the platelet li¬
poxygenase (Nugteren, 1975), it is a much poorer substrate
for the prostaglandin cyclo-oxygenase than arachidonic
acid (Falardeau et al, 1976). As a result, under similar
incubation conditions, relatively more dihomo-y-linolenic
acid (in comparison to arachidonic acid) would be avail¬
able for the platelet lipoxygenase and therefore THEDA
formation may be more pronounced than THETA formation,
which may explain why these workers only detected the
dihomo-y-linolenic acid product.
The role(s) of THETA and EPHETA in platelet functions like
the role(s) of 12-HPETE and 12-HETE are not understood.
It is interesting that both the platelet epoxide EPHETA
and 12-HETE have been found to possess chemotactic activity
for rabbit peritoneal and human peripheral blood PMNL
respectively. It has still to be determined if EPHETA is
chemotactic for human peripheral blood PMNL and also if
12-HETE is chemotactic for rabbit peritoneal PMNL. The
role(s) of hydroxylated and epoxidised fatty acids as
chemoattractants and the determination of which compounds
possess this type of activity are relatively unexplored
subjects.
The recent investigations of workers at the Karolinska
Institute concerning the metabolism of arachidonic acid by




Cysteinyl adducts of linoleic acid hydroperoxide
COOMe
Additional product identified (following methylation)
and Samuelsson, 1976, 1979, 1979a and 1979b). have re¬
sulted in the identification of a number of hydroxylated
and epoxidised arachidonic acid derivatives as products:
5-HETE, 5,12-DHETE, 15-HETE and a 5,6-epoXy compound
(Leukotriene A). It was proposed (Samuelsson, Borgeat,
Hammarstrttm and Murphy, 1979) that the unstable 5,6-
epoxy compound (Leukotriene A) was formed from 5-HPETE
and was the precursor to SRS (Leukotriene C). Leuko¬
triene C was ciSimonstrated to be a novel cysteinyl deri¬
vative of arachidonic acid with a hydroxy1 group at C-5,
three conjugated and one isolated double bonds with the
amino acid linked as a thioether to C-6 (Figure 1.4).
Further work will doubtless be centred on this newly
identified pathway - it is noteworthy that it still has
to be demonstrated that Leukotriene C and SRS-A are
identical.
It should be possible to chemically prepare cysteinyl
adducts of arachidonic acid (other than Leukotriene C)
including the adduct of the platelet epoxide EPHETA. It
will then be interesting to compare the biological acti¬











Figure 6.3 Analogous reaction products of 12-HPETE and
15-HPETE
It is interesting to note that the formation of cysteinyl
adducts from linoleic acid hydroperoxide (13-hydroperoxide)
following treatment with cysteine in the presence of
ferric chloride in 20% aqueous ethanol under nitrogen has
been reported (Figure 6.2a). The corresponding N-acetyl
cysteinyl adducts were isolated when N-acetyl cysteine was
used in place of cysteine (Gardner, Weisleder and Kleiman,
1976) Gardner, Kleiman, Weisleder and Inglett, 1977).
When the reaction with cysteine included both isomers of
linoleic acid hydroperoxide (13- and 9-hyd.roperoxide) and
air, an additional product was isolated (Figure 6.2b)
(Gardner et al, 1977). The formation of these adducts is
not analogous to the previously mentioned leukotriene
pathway. However, this reaction is a potential route for
the preparation of other cysteinyl derivatives of arachi-
donic acid. The analogous reaction products of 15-HPETE
and 12-HPETE are shown in Figure 6.3. It is noteworthy
that the 12-HPETE adduct is substituted at the same
positions in the carbon chain as 8,9,12-THETA. The
preparation of these adducts and the determination of
their biological activity is one of many possible areas
for further research.
Future interest will certainly be focussed on SRS-A and
the newly identified leukotriene pathway, in addition to
further work on the platelet lipoxygenase and the prosta¬
glandin/thromboxane pathways. It is striking that the
vast quantity of information concerning the metabolism
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(and metabolites) of arachidonic acid (and dihomo-y-
linolenic acid) has been acquired over a relatively short
period of time. It is now only 15 years since Van Dorp
et al ( 1964) and Bergstrflm. et al (1964) discovered that
arachidonic acid and dihomo-y-linolenic acid were
prostaglandin precursors!
The importance of arachidonic acid (and to a lesser extent
dihomo-y-linolenic acid) metabolites in physiology and
potentially medicine place them in the forefront of
chemical, biochemical and pharmacological investigations.
Despite the rapid advances made during the last 15 years,
the understanding of the physiological roles of these
compounds is far from complete.
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THE IDENTIFICATION OF TRIHYDROXYEICOSATRIENOIC ACIDS
AS PRODUCTS FROM THE INCUBATION OF ARACHIDONIC ACID
WITH WASHED BLOOD PLATELETS








Arachidonic acid is converted by washed platelets
from man, horse and dog into a mixture of 8,9,12-trihydroxy-
eicosa-5,10,14-trienoic acid and 8,11,12-trihydroxyeicosa-
5,9,14-trienoic acid (termed 8,9,12-THETA and 8, 11, 12-
THETA respectively and THETA collectively). Gas chromato¬
graphic - mass spectrometric evidence of structure is
discussed.
INTRODUCTION
Rapid metabolism of arachidonic acid occurs in human
platelets by two pathways. Fatty acid cyclo-oxygenase
generates PGG2 and PGH2 which are then enzymatically
isomerised to thromboxane A2, a very potent stimulant of
platelet aggregation (1). Lipoxygenase action also produces
12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid which is
subsequently transformed to 12-hydroxyeicosa-5,8,10,14-
tetraenoic acid (HETE) (2). Our studies with human, horse
and dog platelets have revealed the presence of further
novel metabolites of arachidonic acid.
EXPERIMENTAL PROCEDURE AND RESULTS
Platelet rich plasma and washed platelets from
citrated human, horse and dog blood were prepared accord¬
ing to Hamberg ejt al (3). Washed platelets (at a
concentration of 5 x 108 - 5 x 109 ml 1) were incubated with
arachidonic acid (1.65 x 10~4 M) at 37°C for 30 min. In
some experiments l-w C-arachidonic acid (final sp. activity
120 UCi mmole 1) was added as tracer to incubates.
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After acidification, the products were extracted with
diethyl ether; non-polar lipids were then removed by
partition between 67% ethanol and petroleum ether.
Initial work, which involved purification of the
methyl ester of the incubation extract by liquid-gel
partition chromatography (4) and HPLC (Partisil PAC,
hexane/isopropanol 4:1), afforded a single zone of radio¬
activity, slightly less polar than PGF2(X, which was free
of PGD2, PGE2, PGF2Ct and TXB2. GC-MS studies indicated
the presence of a mixture of 8,9,12-trihydroxyeicosa-
5,10,14-trienoic acid (8,9,12-THETA) and 8,11,12-
trihydroxy-eicosa-5,9, 14-trienoic acid (8,11,12-THETA).
Complete separation of the two positional isomers was
subsequently achieved by liquid-gel chromatography of the
free acid of the incubation extract. The data discussed


























Fig. 1. Mass spectrum of 8,11,12-THETA (Me/TMS).
Gas chromatography of the methyl ester-trimethylsilyl
ether (Me/TMS) derivatives of both compounds showed two
partially resolved peaks (carbon values 23.6 and 23.8 on a
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3% 0V1 column). From mass spectrometric analysis the
partially resolved GC peaks were shown to be isomers with
very similar mass spectra. The Me/TMS derivative of the
more polar positional isomer on liquid-gel chromatography
showed prominent ions in both mass spectra taken at carbon
values 23.6 and 23.8 at m+/e 569 (M-15), 479 (M-15-90),
463 (M-31-90), 383 (M-90-111), 371 (M-213), 353 (M-90-141),
281 (M-90-213), 243 (CH(OTMS) CH2 CH = CH (CH2)3 COOMe),
230 (M-141-213 or -111-243), 213 (CH( OTMS) CH2 CH = CH C5H1t)
(base peak). (Fig. 1). These mass spectra are consistent
with isomers of 8,11,12-THETA. The ethyl ester-
trimethylsilyl ether spectra were consistent with these
assignments.
The Me/TMS derivative of the less polar positional
isomer on liquid-gel chromatography showed prominent ions
in both mass spectra taken at carbon values 23.6 and 23.8
at m+/e 569 (M-15), 479 (M-15-90), 463 (M-31-90), 383
(M-90-111), 353 (M-90-141), 251 (M-90-243), 243 (CH(OTMS)
CH2 CH = CH (CH,)3 COOMe) (base peak) 230 (M-141-213 or
-111-243), 213 (CH(OTMS) CH2 CH = CH CsH,, ) (Fig. 2).
Fig,. 2. Mass spectrum of 8,9,12-THETA (Me/TMS).
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These mass spectra are consistent with isomers of
8,9,12-THETA. The ethyl ester-trimethylsily1 ether spectra
were consistent with these assignments. It should be
noted that the Me/TMS derivative of 9,10-dihydroxystearic
acid undergoes one major fragmentation in the mass spectro¬
meter - between C9 and CIO, indicating that fragmentation
takes place preferentially between two adjacent TMS-
substituted hydroxyl groups on the chain of a fatty acid.
Following hydrogenation (platinum oxide/methanol) and
Me/TMS derivitisation both compounds still showed two
partially resolved GC peaks (carbon values 24.4 and 24.7).
The mass spectra indicated that the partially resolved GC
peaks were isomers and the spectra of both compounds
indicated the presence of three double bonds in the
original materials. The mass spectra of the 8,11,12-THETA
isomers showed a base peak at m+/e 285 (M-215-90), and
large ions at m+/e 215 (CH(OTMS) C8H17) and 245 (CH(OTMS)
(CH2)6 COOMe). In the spectra of the 8,9,12-THETA isomers
m+/e 255 (M-245-90) was the base peak and large ions were
again observed at m+/e 215 and 245. Multiple ion detection
of the 245 and 215 ions of both compounds (Fig. 3)







Fig. 3. Multiple ion detection of m+/e 215 and 245
ions from 8,11,12-THETA and 8,9,12-THETA
(Me/hydrogenated/TMS).
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The hydrogenated forms of both compounds formed a
n-butyl boronate/mono-TMS derivative supporting the
presence of vicinal hydroxyl groups. Two partially
resolved GC peaks were observed for both compounds (carbon
values 26.0 and 26.2). The mass spectra of both GC peaks
of this derivative showed m+/e 245 as the base peak of
8,11,12-THETA and m+/e 215 as the base peak of 8,9,12-
THETA. (Fig. 4). Multiple ion detection of the 215 and
245 ions again supported the existence of the stereo¬




Fig. 4. Fragmentation of 8,11,12-THETA and
8,9, 12-THETA (Me/hydrogenated/n-buty1
boronate/TMS).
The mixture of positional isomers did not react with
O-methylhydroxylamine, and showed no diene absorption in
the ultraviolet region. Further work is required to
establish the configurations of the hydroxyl groups and
the double bonds (it is probable that the 5,6 and 14,15
bonds have remained cisl.
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In incubations with washed human platelets THETA was found
to be a major metabolite since it has been detected in
comparable amounts to HETE and in greater amounts than
thromboxane B, Washed horse platelets consistently
produced more than 100 times the amount of THETA compared
to thromboxane B2. Similar material has also been found
following incubations of arachidonic acid with sheep
uteri and sheep spleen homogenates. The formation of
THETA was not blocked by indomethacin (10 5M).
It is of interest to note that Samuelsson and co¬
workers isolated the corresponding trihydroxy - dienoic
acids from incubation of bis-homo-y-linolenic acid with
human platelets but were unable to establish a similar
conversion from arachidonic acid (5).
A possible mechanism suggested for the formation of
THETA is the transformation of 12-hydroperoxyeicosa-
5,8,10,14-tetraenoic acid via an epoxy-hydroxy inter¬
mediate; analogous conversions of linoleic acid incubated




A possible mechanism of THETA formation.
The biological properties of THETA are under
investigation.
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ABSTRACT
Arachidonic acid is converted by platelets into a mixture of 8,11,12-
trihydroxyeicosa-5,9,14-trienoic acid and 8,9,12-trihydroxyeicosa-
5,10,14-trienoic acid (termed 8,11,12-THETA and 8,9,12-THETA respect¬
ively and THETA collectively). GC-MS evidence of structure is dis¬
cussed along with possible precursors of THETA formation and related
substances.
INTRODUCTION
Arachidonic acid is the essential fatty acid precursor to the 2-series
prostaglandins (1). An alternative metabolic pathway, via a lipoxy¬
genase enzyme, is known to exist in blood platelets of mammals, yield¬
ing 12-hydroperoxy- and hence 12-hydroxy-eicosa-5,8,10,14-tetraenoic
acid (2). Further study has revealed additional lipoxygenase activity
in the conversion of arachidonic acid into 8,11,12-trihydroxyeicosa-
5,9,14-trienoic acid and 8,9,12-trihydroxyeicosa-5,10,14-trienoic acid
(8,11,12-THETA and 8,9,12-THETA).
METHODS
Platelet rich plasma and washed platelets from citrated human, horse
and dog blood were prepared in the usual manner (3). Incubations
with radiolabelled 1-14C arachidonic acid (1.65 x 10"*M; Sp. Ac.
120 pCi/mmole) were performed at 37°C for 30 minutes. After acidifi¬
cation to pH 4, the products were extracted with ether and the ether
evaporated. The non-polar lipids were removed by partition of the
material between 67% ethanol and petroleum ether. The polar lipids
were isolated by evaporation of the alcoholic phase. The material
was treated with diazomethane to form the methyl esters and purifi¬
cation by liquid-gel partition chromatography (4) and HPLC gave a
single zone of radioactivity slightly less polar than PGFaa. The
wide unsymmetrical peak was due presumably to the subsequently dis¬
covered isomers. This material (THETA) had no diene absorption in
the U.V. Gas chromatography-mass spectrometry of the Me,TMS deriv¬
ative showed the presence of at least two substances which could be
assigned the trihydroxyeicosatrienoic acid constitution. The material
formed no oxime derivative. Complete resolution of these isomers
was achieved by liquid-gel partition chromatography of the free acid
THETA (Fig. 1.).
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RESULTS AND DISCUSSION
GC-MS of the separated isomers was performed on 3% OVI. The more
polar, major isomer, 8,11,12-THETA, consisted of two partially
resolved peaks (C.V. 23.6, 23.8), run as Me,TMS. Both G.C. isomers
in this fraction had almost identical mass spectra.
FRACTION (24min)
Fig. 1. Chromatogram of polar lipid fraction
run as free acids
The structural analysis is shown in Fig.2., the large peak at /e 213
being the well documented favourable cleavage between the vicinal-OTMS
groups. The less polar, minor isomer, 8,9,12-THETA, showed very
similar G.C. profile, again with two partially resolved peaks (C.V.
23.6, 23.8) with almost identical mass spectra (Fig. 3).
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Fig. 3. M.S. of 8 , 9,12-THETA Me,TMS
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The 8,9,12-THETA isomers are characterised by the large peak at /& 243
All peak assignments in all isomers were checked using the Et,TMS
derivatives.
The remaining isomerism in the substances is thought to be due to
hydroxyl diastereoisomers. However, it was necessary to remove the
possibility of cis-trans isomerism by hydrogenation of all olefinic
bonds. Both THETA molecules took up 3 molecules of hydrogen in the






Fig. 4. M.I.D. of /e 215 and 245 ions from hydrogen-
ated 8,11,12-THETA and 8,9,12-THETA run as
Me,TMS derivatives
The mass spectra of the hydrogenated THETA as Me,TMS and the structural
analysis is given in Figs. 5 and 6. In the 8,11,12-isomers the base
peak £ 285 is due to (M-215-90), the peak at M 267 is (M-143-90 x 2).
All other fragmentations are fairly simple cleavages due to loss of
90 a.m.u. (TMSOH) and 31 a.m.u. (-OMe). Similarly in the 8,9,12-
isomers the base peak fe 255 is due to (M-245-90) and the peak at
/a 387, (M-113-90). These assignments were checked with the Et,TMS
derivatives.
This GC-MS evidence leaves little doubt that the isomerism remaining
in the positional isomers of THETA is due to diastereoisomerism at
the hydroxyl groups.
142 R. L. Jones et al.
Fig. 5. M.S. of hydrogenated 8,11,12-THETA as
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Fig. 6. M.S. of hydrogenated 8,9,12-THETA as
Me,TMS (C.V. = 24.4, 24.7)
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Final structural proof of the hydroxyl positions was provided by
altering the mass spectral fragmentation of the hydrogenated THETA by
formation of the cyclic n-butyl boronate ester. This is known only to
form with 1,2 or 1,3-diols. The mass spectra and the analysis are
given in Figs. 7 and 8.
257. *9
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Fig. 7. M.S. of hydrogenated 8,11,12-THETA as


























M.S. of hydrogenated 8,9,12-THETA as
Me,nBB,TMS derivative (C.V. = 26.0, 26.2)
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Assignment of peaks was assisted by the boron isotope pattern
C°B 20%, 11B 80%) e.g. the large peak at /e 279 (Fig. 7) occurs by loss
of 90,(TMS0H), from the 369 peak. Both these peaks contain a boron
atom. The corresponding peaks in Fig. 8 are at M 309 and 399.
So far no biological role has been found for THETA other than the
possible removal of arachidonate as a more polar metabolite. The
importance of such metabolic pathways is therefore not appreciated at
present, but may be considerable especially when PG biosynthesis is
inhibited by drugs (indomethacin, aspirin). The quantity of THETA
compared to TXBa formed, varies considerably even in the same subject.
Washed platelets appear to give more THETA than the platelet-rich
plasma incubations (Fig. 9). The best source of THETA is washed horse
platelets. It is also formed by sheep and guinea-pig uterus, sheep
and dog spleen. Its formation is not inhibited by aspirin-like drugs.
THETA has very weak (spasmogenic) action on smooth muscle preparations,








Fig. 9. Incubation of arachidonic acid with platelets
under different conditions. Analysis by MID
of characteristic ions.
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It is of interest to note that Samuelsson and his co-workers isolated
analogous trihydroxy acids from dihomo-y-linolenic acid incubations
with human platelets, but were unable to establish a similar conversion
for arachidonic acid (5). A mechanism suggested by the Swedish workers
for the formation of such trihydroxy systems is the hydration of an
epoxy-hydroxy system, derived by further oxidation of the 12-hydro-
peroxyeicosa-8,10,14-trienoic acid. These epoxy systems have some
precedent in fatty acid oxidations (6).
8,11,12—THETA 8,9,12-TH ETA
Fig. 10. Proposed mechanism of THETA formation f5)
This is not, however, the only mechanism but seems a likely possi¬
bility. Accordingly, we have looked for the intermediate epoxy com¬
pound in our analysis and we have found a possible candidate. The
slightly more polar shoulder on the HETE peak in Fig. 1. appeared to
be an epoxy derivative of arachidonic acid, as suggested by GC-MS data
(Fig. 11). The position of the hydroxyl group has not yet been deter¬
mined finally, although it is likely to be in the 8-position. The peak
at /e 269 has the constitution shown (Fig. 11) by exact mass measure¬
ment. This compound may well be the intermediate precursor to THETA.
Its final chemical structure and biological actions obviously require
investigation.























Fig. 11. Possible structure for substance in HETE
fraction (Fig. 1).
Me,TMS derivative (C.V. = 22.0)
Finally we should like to speculate that these molecules, in particular
the THETA precursor/s and 8,11,12-THETA could be related to the struc¬
tures described by Pace Asciak some years ago (7) (Fig. 12). Detection
of the first species (A) has eluded this laboratory although we have
found the second substance (B) in very small quantities in the dog
spleen, as indicated by its mass spectrum (Fig. 13). This substance
does not form an oxime derivative, though oximation of the material
extracted was required so as to shift the G.C. retention times of
interfering prostanoids, for example, 6-oxo-PGFia and thromboxane Bz.

































M.S. of prostanoid isolated from dog
spleen, 8,12-oxy-9,11,15-trihydroxy-
eicosa-5,13-dienoic acid.
Me,TMS derivative (C.V. = 24-2)
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These structures (Fig. 12) have oxygen functions in the same positions
as in THETA though a further hydroxyl requires to be introduced at the
15-position. This raises the intriguing possibility of an interaction
between the lipoxygenase and the cyclo-oxygenase pathways.
This work was supported by an M.R.C. grant to Professor E. W. Horton.
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PROSTAGLANDINS
THE IDENTIFICATION OF AN EPOXY-HYDROXY ACID AS A
PRODUCT FROM THE INCUBATION OF ARACHIDONIC ACID
WITH WASHED BLOOD PLATELETS







An epoxy-hydroxy compound, 10-hydroxy-ll,12-epoxy-
eicosa-5,8,14-trienoic acid, has been identified as a
product on incubation of arachidonic acid with washed
blood platelets from human, horse, cat, dog and rabbit.
Gas chromatographic - mass spectrometric (GC-MS)evidence
of structure is discussed.
Introduction
Rapid metabolism of arachidonic acid occurs in
human platelets by two main pathways. Fatty acid cyclo-
oxygenase generates PGG2 and PGH2 which are then
enzymatically isomerised to thromboxane A2, a very potent
stimulant of platelet aggregation (1). Lipoxygenase
action also produces 12-hydroperoxyeicosa-5,8,10,14-
tetraenoic acid (HPETE) which is subsequently trans¬
formed to 12-hydroxyeicosa-5,8,10,14-tetraenoic acid
(HETE)(2). Our recent studies with washed platelets have
resulted in the identification of two trihydroxy acids -
8,11,12-trihydroxyeicosa-5,9,14-trienoic acid and 8,9,12-
trihydroxyeicosa-5,10,14 trienoic acid (THETA)(3). A
possible mechanism suggested for the formation of these
trihydroxy acids was the conversion of HPETE to 8-
hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid and
subsequent hydration of this epoxide. During attempts to
detect this hydroxy-epoxy intermediate an analogous
compound was detected (4). Further structural identifica¬
tion work on this compound by GC-MS of various derivatives
indicates the structure to be 10-hydroxy-ll,12-epoxy-
eicosa-5, 8 , 14-"trirenoic acid ( EPHETA) .
Experimental Procedure and Results
Platelet rich plasma and washed platelets from
citrated human, horse, cat, dog and rabbit blood were
prepared according to Hamberg ei &L (5). Washed
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platelets (at a concentration of 5 x 108 - 5 x 109 ml"1)
were incubated with arachidonic acid (1.65 x 10~4M) in a
Krebs-Henseleit medium (containing neither calcium ions
nor glucose) at 37°C for 30 min. In some experiments
1-1 4C-arachidonic acid (final sp. activity 120 U-Ci mraole"1)
was added as tracer to incubates. After acidification,
the products were extracted with diethyl ether and the
organic extract purified by liquid-gel partition chromato¬
graphy (4). By scintillation counting of the column
eluate, a more polar shoulder on the HETE peak was
detected. This material was subjected to GC-MS analysis.
Gas-chromatography of the methyl ester-trimethy1
silyl ether (Me/TMS) derivative showed a single peak
(carbon value 22.05 on a 3% OVI column). The mass spectrum
indicated a compound with molecular weight of 422 as ions
were observed at m+/e 422, 407 (-CH3) and 391 (-0CH3).
This is consistent with a C20 fatty acid methyl ester
having three double bonds, one trimethylsilyloxy group and
one keto or epoxy oxygen. Additional significant ions
were observed at m+/e 332 (-TMSOH), 311 (-111), 282/281
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Figure 1. Mass spectrum of EPHETA (Me/TMS).
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The material did not form an oxime indicating the
absence of a carbonyl group. In the ethyl ester-
trimethysilyl ether derivative (carbon value 22.6) the
base peak was found at m+/e 283 suggesting that this ion
and that at m+/e 269 in the methyl ester spectrum contain
the ester group. Similarly, significant ions were
observed at m+/e 296/295 suggesting that these ions and
those at 282/281 in the methyl ester spectrum contain the
ester group - these ions are interpreted as resulting
from the transannular cleavage of the epoxide, which
occurs with and without proton transfer (6). This
evidence is consistent with the proposed structure of
EPHETA.
Following hydrogenation (platinum oxide/methanol)
and Me/TMS derivitisation the material showed two
marginally separated GC peaks (C values 22.80, 22.85).
The mass spectra taken at these C values were very
similar and indicated the presence of three double bonds
in the original material. As oleic acid epoxide was
unchanged by the hydrogenation procedure it may be
assumed that an epoxide group would be unaffected.
Significant ions were observed at m+/e 413 (-CH3), 397





Figure 2. Fragmentation of EPHETA (Me/hydrogenated/TMS).
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The ion at m+/e 273 confirmed the presence of two double
bonds in the fragment m+/e 269 in the Me/TMS spectrum of
the original material, and the ion at m+/e 257 was
indicative of a hydroxyl group at the 10 position (Fig.2).
It is possible that either hydroxyl stereoisomers or
epoxy isomers of this compound are present since multiple
ion detection of the major ions in the spectra also
indicated two very slightly resolved peaks in the
respective single ion chromatograms.
It is well known that lithium aluminium hydride
(LiAlH4) reduces an epoxide grouping to a mono-alcohol
(two positional isomers are usually formed). During this
reaction an ester group is also reduced to a primary
alcohol. The isolated material (250 Ug as the methyl
ester) was therefore heated with LiAlH4 in dry tetra-
hydrofuran at 60°C for 72 h. in an ampoule sealed under
nitrogen. Gas chromatography of the TMS derivative of
the product showed a single peak (carbon value 23.0),
whose mass spectrum had significant ions at m /e 540
(molecular ion), 525 (-CH3), 450 (-TMSOH), 313, 227 and







v formation followed by
» TMS ether formation
Figure 3. Reaction scheme for LiAlH4 reduction.
176 AUGUST 1979 VOL. 18 NO. 2
PROSTAGLANDINS
The relative abundance of the ions at m+/e 313, 227 and
213 altered in spectra taken at different positions on
the GC peak, suggesting the presence of two slightly
resolved products.
Gas chromatography of the n-butyl boronate/
trimethylsily1 ether of the product of the LiAlH4
reduction indicated that none of the TMS product remained
and showed two partially resolved peaks (C values 23.8 and
24.2) with very similar mass spectra. Both these spectra
contained the expected molecular ion, m+/e 462, and were
consistent with the proposed products (Fig. 3). The mass
spectra were dominated by cleavages involving the boro¬
nate and trimethylsilyloxy groups and therefore it is not
possible to tell whether the two GC peaks correspond to
the two different products although this seems the most
likely explanation. Since 1,2- and 1,3- diols readily
form boronates, the formation of these derivatives
indicates the hydroxyl group was adjacent to the epoxide
in the original molecule.
All the evidence indicates the structure of this
molecule as 10-hydroxy - 11,12-epoxyeicosa-5,8,14-trienoic
acid and not the proposed THETA intermediate 8-hydroxy-
11,12-epoxyeicosa-5,9,14-trienoic acid. Further work is
required to establish the configurations of the hydroxyl
and epoxy groups (it is probable that the 5,6; 8,9 and
14,15 double bonds have remained cis). In incubations
with washed platelets this molecule has been detected in
smaller quantities than THETA (approximately 1/4 the
amount) and on occasions in comparable amounts to
thromboxane B2. The formation of EPHETA was not blocked
by indomethacin (10~5M).
A possible mechanism suggested for the formation of
EPHETA is the transformation of the HPETE (at present
there is no evidence that this conversion is enzymatic);
analogous conversions of C18 fatty acid hydroperoxides
have been reported (7).
Non-allylic epoxy-hydroxy acids are considerably
more stable towards nucleophiles than allylic epoxy-hydroxy
acids (8). It would therefore seem likely that both 8-
hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid (an allylic
epoxy-hydroxy acid) and 10-hydroxy-ll,12-epoxyeicosa-5,8,
14-trienoic acid (a non-allylic epoxy-hydroxy acid) form
from HPETE. Only the more stable lC-hydroxy compound
(EPHETA) accumulates whereas the less stable 8-hydroxy
compound is converted to the two trihydroxy acids (THETA)
by the addition of water.
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The biological properties of EPHETA are under
investigation.
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